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ABSTRACT 
 
Tauopathies are neurodegenerative diseases that affect millions of people around 
the world. Tauopathies include more than 20 neurodegenerative diseases. Some of the 
most common tauopathies are Alzheimer’s disease (AD), frontotemporal dementia (FTD), 
chronic traumatic encephalopathy (CTE), Pick’s disease, corticobasal degeneration, 
progressive supranuclear palsy (PSP), agyrophillic grain disease, and amyotrophic lateral 
sclerosis (ALS). These diseases can cause significant memory loss, behavioral changes, 
motor deficits and speech impairments. Tauopathies stem from accumulation of the 
microtubule associated protein tau (MAPT). Tau stabilizes microtubules and helps with 
axonal transport. In a disease state tau becomes hyperphosphorylated and truncated 
leading to its aggregation. More recently tau has been shown to propagate from cell to 
cell potentially acting as a signaling molecule that contributes to disease progression. In 
addition during disease, tau mislocalizes to dendrites leading to synaptic dysfunction. This 
mislocalization may also lead to subsequent neurodegeneration.  
Today, many strategies have been implemented to treat tauopathies. Some of 
these strategies include kinase inhibitors, immunotherapy, tau aggregation inhibitors, and 
microtubule-stabilizing compounds. However none these strategies have been effective 
in stopping tau pathology nor do they address tau degradation pathways. Therefore we 
hypothesized that utilizing small molecules that target degradation pathways such as 
autophagy or proteasomal degradation would improve clearance of aberrant tau. 
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 We previously showed that a natural product (+)-aR,11S-myricanol (1) from 
Myrica cerifica (bayberry/southern wax myrtle) root bark reduced levels of tau. In this 
study we discovered that 1 is composed of two enantiomers and two possible 
atropisomers. We found that one enantiomer (-)-aS,11R-myricanol (3) was responsible 
for the anti-tau activity of 1 in multiple models of tauopathy. We also found that 3 
selectively targets and lowers specific tau species. To better understand how these tau 
species were being reduced we took a non-biased approach and subjected 3 treated 
samples to stable isotope labeling by amino acids in cell culture (SILAC) mass 
spectrometry (MS) proteomic analysis. We found that autophagy pathways were most 
affected by 3 and that 3 was predicted to mimic the drug rapamycin, a well-established 
macroautophagy activator. In addition we confirmed our MS findings by simultaneously 
giving 3 treated cells an autophagy inhibitor which blocked 3’s tau reductions. Moreover 
we created a tetralin derivative of 1, 13, that produced the same effects on tau as 3 but 
did not rely upon stereochemistry for its activity. This work supports targeting the 
autophagy degradation pathway as a viable approach to improving aberrant tau 
accumulation. 
In order to further support our hypothesis, we collected and screened several 
known heat shock protein 70 (Hsp70) inhibitors and tau aggregation inhibitors for cellular 
anti-tau activity. While it is known that Hsp70 inhibition facilitates tau clearance through 
proteasomal degradation, it is not known what role tau aggregation inhibition plays in the 
cellular degradation of tau. Moreover understanding which inhibitory activity contributes 
most to tau degradation would lead to the creation of better drug scaffolds. In this study, 
we found that several Hsp70 inhibitors from different scaffold backbones had varying 
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effects on tau degradation. The rhodacyanine and phenothiazine compounds were most 
effective at lowering cellular tau while the adenosine analog, sulfonamide, 
dihyropyrimidine, piperidine-3-carboxamide, phenoxy-N-arylacetamide, and flavonol, 
were not as effective. We also examined the effects of several tau aggregation inhibitor 
scaffolds such as the carbocyanine, oleuropein, anthraquinone, aminothienopyridazine, 
hydroxytyrosol and rhodanine on tau expression reduction. We found that none had 
effective tau reductions except the carbocyanine. However when we performed a lactate 
dehydrogenase (LDH) assay, carbocyanine was shown to be extremely toxic. These 
results lead us to further investigate if the tau expression reducing Hsp70 inhibitors had 
anti-tau aggregation activity and if the tau aggregation inhibitors had any Hsp70 inhibitory 
activity. We discovered that many of the Hsp70 inhibitors also had anti-tau aggregation 
activity while none of the aggregation inhibitors had Hsp70 inhibitory activity. We found a 
positive correlation between tau expression reductions and anti-tau aggregation activity 
for the Hsp70 inhibitors. Our work demonstrates that both Hsp70 activity and tau 
aggregation in vitro best predicts anti-tau activity of small molecules. Also these dual 
acting Hsp70 inhibitors support our hypothesis that targeting the degradation pathways 
can improve tau clearance. 
Overall, this work indicates the importance of targeting degradation pathways to 
improve tau clearance. Utilizing small molecules that have dual activities against tau could 
prove beneficial as a novel therapeutic approach to treat tauopathies. In addition using 
small molecules that target different degradation pathways simultaneously could be 
another viable therapeutic strategy for treatment of tauopathies.      
 
1 
 
 
 
 
 
 
CHAPTER ONE: 
 
RATIONALE FOR TARGETING TAU DEGRADATION FOR TREATMENT OF 
TAUOPATHIES 
1.1 Tau Biology 
Tau is an intrinsically disordered cytosolic 441 amino acid (aa) protein which binds 
to microtubules and promotes microtubule assembly.1 It is mainly located in the axons of 
neurons found in the central and peripheral nervous systems.1 As a result tau can regulate 
axonal transport.1-3 More specifically tau can help motor proteins detach their cargo to 
increase axonal transport efficiency. In contrast tau can also inhibit kinesin and dynein 
trafficking to prevent axonal transport to the synapse.4, 5 Another function of tau is that it 
can bind and bundle actin filaments which can lead to neurodegeneration.6 Also more 
recently tau has been thought to be an external signaling molecule.3 Tau has been shown 
to be released into the extracellular space from healthy or dying neurons allowing it to 
propagate to neighboring cells like a prion.7-10  In disease tau mislocalizes to the dendritic 
compartment of the neuron.11-13 Many in the field believe this and its subsequent release 
act to progress disease as well send signals to neighboring cells. However the 
mechanism of tau release has remained elusive but our lab and others have suggested 
tau may be released by SNARE mediated exocytosis or exosomal release.14, 15 This 
phenomenon has caused tau to become a major drug target in multiple diseases termed 
tauopathies. Tauopathies are neurodegenerative diseases that develop from the 
abnormal accumulation of tau. Two of the most prevalent tauopathies are AD and FTD.16 
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In both AD and FTD patients experience memory loss, behavioral changes, motor deficits 
and speech impairments.16 Despite these diseases being so common, there are no 
treatments that stop the pathology. Therefore a better understanding of what role tau 
plays in these diseases and how to prevent its accumulation and release could provide 
new therapeutic approaches to treat tauopathies.  
Genetically, tau is located in locus 17q21.3.17 Tau has 16 exons three of which are 
alternatively spliced (exons 2, 3, and 10) in the central nervous system to generate six 
isoforms; 4R2N, 4R1N, 4R0N, 3R2N, 3R1N, or 3R0N tau.17 Additionally in the peripheral 
nervous system exon 4A is included in tau to form the largest form of tau known as “Big 
Tau”.18 In these isoforms R represents the number of repeats domain while N represents 
the number of N-Terminal inserts.  Exons 2 and 3 correspond to tau’s N-Terminal inserts 
and exon 10 to the second region of tau’s microtubule binding repeat domain.17 These N-
Terminal inserts are part of the projection domain that allows tau to interact with the cell 
membrane.19  In addition tau has four microtubule binding repeat domains (MBD).17 
These domains are composed of a KXGS conserved motif with the positively charged 
amino acid lysine (K), which helps allow tau to bind to the negatively charged 
microtubules. In adult humans the most common isoform is 4R0N tau while 3R0N tau is 
the most common in the fetal brain.20 Alterations in the ratio of 4R0N to 3R0N can lead to 
disease.20 In addition, tau may undergo a variety of post-translational modifications such 
as ubiquitination, glycation, nitration, sumolyation, glycosylation, isomerization, 
methylation, acetylation, polyamination, oxidation, truncation and most notably 
phosphorylation.17 Tau has approximately 85 putative phosphorylation sites. There are 
45 serines, 35 threonines, and 5 tyrosines sites. Moreover several kinases phosphorylate 
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tau. Some of these include glycogen synthase kinase-3β (GSK3β), cyclin-dependent 
kinase-5 (CDK5), mitogen-activated protein kinase (MAPK), casein kinase 1 (CK1), dual-
specificity tyrosine phosphorylation and regulated kinase 1A (DYRK1A), microtubule 
affinity-regulating kinases (MARKs), protein kinase cyclic adenosine monophosphate 
(cAMP)-dependent, protein-tyrosine kinase Fyn (Src Kinase) and Ca2+/calmodulin-
dependent protein kinase II (CaMKII). With this in mind, phosphorylation of tau’s serines 
in the MBD can lead to decreased binding to the microtubule which in turn can lead to the 
hyperphosphorylation of tau.17  Tau hyperphosphorylation is defined as a rise in the 
number of sites phosphorylated and/or as an increase in the number of tau molecules 
phosphorylated.17 Additionally, hyperphosphorylation of tau can be caused by mutations 
in tau or pathological events that cause microtubule destabilization such as amyloid β 
misprocessing. There are more than 50 mutations that have been found in tau which have 
been associated with disease. More importantly, mutations found in the microtubule 
binding region such as P301L, V337M, and G303V can lead to tau 
hyperphosphorylation.21 In addition axonal injury from traumatic brain injury (TBI) and 
degradation pathway misprocessing can cause the hyperphosphorylation of tau.22-26 Most 
importantly the hyperphosphorylation of tau leads to the formation of toxic aggregates.17 
Tau aggregation is the main hallmark of many tauopathies.  
 
1.2 Tau Aggregation 
Tau aggregation occurs in a multistep process after the hyperphosphorylation of 
tau. Soluble hyperphosphorylated tau molecules (tau monomer) first dimerize with each 
other to form dimers. Next the dimers polymerize to form oligomers. The oligomers then 
4 
 
assemble to form protomers.17  These protomers then organize into insoluble paired 
helical filaments (PHFs). The PHFs then mature into neurofibrillary tangles (NFTs) which 
are the most common biomarker in tauopathies such as AD, CTE, and FTD.27, 28 Moreover 
tau can aggregate through self-aggregation or binding to native tau not bound to 
microtubules. One way in which these aggregates form is tau having two naturally 
occurring cysteine residues located in the microtubule binding domain. These cysteines 
allow tau to form intermolecular disulfide bonds with neighboring tau molecules leading 
to tau aggregates.29-32 Another way in which these aggregates form is through the 
interaction of two hexapeptide motifs found in the second and third MBD of tau. The motifs 
275VQIINK280 and 306VQIVYK311 interact through hydrogen (H) bonding between separate 
tau molecules.33 In addition there is a tyrosine(Y)-tyrosine aromatic interaction which 
stabilizes the β-sheets to allow the formation of the PHFs. While mature PHFs, NFTs, 
were once perceived to be the toxic species causing neuronal cell death, it is now believed 
that tau oligomers cause neuronal cell death. Evidence has been given showing NFTs to 
be neuroprotective in multiple models of disease.34-36 The formation NFTs is a possible 
mechanism to avoid neurotoxicity. Hyperphosphorylated tau alone disrupts normal tau 
function of microtubule assembly and causes cell death.20 However when 
hyperphosphorylated tau polymerizes to form NFTs, disruption of microtubule assembly 
cannot occur.20 Therefore an intermediate form of tau, tau oligomers, have been reported 
to cause microtubule depolymerization and neurodegeneration.37, 38 In addition many 
studies have suggested that the main form of tau released and transmitted to neighboring 
cells is oligomeric tau.20, 37-40 With this in mind, there is a need for a better understanding 
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of how to improve tau degradation to prevent oligomer formation and subsequent tau 
pathology.  
 
1.3 Tau Degradation 
Many studies have shown that tau is degraded through the ubiquitin-proteasome 
system (UPS) and the autophagy-lysosomal system. The ubiquitin-proteasome system 
regulates and maintains protein levels by abolishing mutant, misfolded or damaged 
proteins.41  There are two pathways for the UPS; ubiquitin (Ub) dependent or Ub 
independent. In the Ub dependent pathway proteins’ lysines are covalently conjugated to 
an ubiquitin molecule or a chain of ubiquitin molecules.41, 42 The chain of Ub is then 
recognized by the proteasome. Once recognized the protein is passed through the 
proteasome and proteolysed by trypsin-like, chymotrypsin-like, and post-glutamyl 
activities into small proteolytic fragments.41, 42 In comparison in the Ub independent 
pathway substrate proteins are able to proceed directly to the proteasome for 
degradation.41, 42  Tau can proceed through both UPS pathways.42 More specifically, full 
length monomeric tau is degraded through the UPS while truncated and insoluble forms 
of tau go through the autophagy-lysosomal system.42, 43 Originally, tau pathology was 
thought to be caused by full length tau forming paired helical filaments (PHFs). Studies 
showed that PHFs were ubiquitinated at three main sites in the MBD which are K254, 
K311, and K353.42 Studies also showed that when the proteasome is blocked by highly 
ubiquitinated tau PHFs this could cause cell death and neurodegeneration.42 These 
ubiquitinated PHFs obstruct the proteasome and make degradation of proteins inefficient. 
This evidence led the field to believe that the misprocessing of ubiquitin-proteasome 
system was the only cause of tau pathology. However more recently cleaved/truncated 
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forms of tau have been shown to create toxic oligomers.44, 45 In addition autophagic 
processing has been shown to decrease with age and in diseased states.24, 46, 47 This led 
the field to more closely investigate the role of autophagy in tau degradation. Unlike 
proteasomal degradation there are three major pathways for autophagy; 
macroautophagy, microautophagy, and chaperone mediated autophagy (CMA). All three 
autophagy pathways involve the lysosome lysing substrate proteins, fragments or other 
cytoplamsic cellular debris.48 More specifically in macroautophagy, the target proteins are 
engulfed by a phagophore which then becomes an autophagosome that fuses with the 
lysosome.48 The newly formed autolysosome then lyses its contents. In comparison in 
microautophagy, invagination of the lysosomal membrane allows cytoplasmic 
components to enter and then be degraded.48 For CMA on the other hand, substrates are 
bound to chaperones and escorted to the lysosome for degradation.48 For tau, 
macroautophagy and CMA have been shown to be most commonly involved in its 
degradation.25 More specifically the Mandelkow group published that chaperone 
mediated autophagy creates cleaved forms of tau or tau fragments which can seed the 
formation of tau oligomers.45 This occurs by the chaperone, heat shock protein cognate 
70 (Hsc70), recognizing the pentapeptide lysosomal targeting motifs in tau (336QVEVK340 
and 347KDRVQ351) and then translocating tau through the lysosome-associated 
membrane protein type 2A (LAMP-2A).45, 49 During the translocation tau becomes stuck 
in the membrane and is cleaved by lysosomal proteases, mainly the cathepsins D and 
L.45, 50 These proteases generate multiple fragments inside and outside the lysosomal 
membrane. The outside fragment most associated with the lysosomal membrane has 
been hypothesized to then seed the formation of tau oligomers in the cytosol.45 In addition 
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they suggested that these aggregates could be degraded by subsequent 
macroautophagy activation. They showed that if you block macroautophagy by chemical 
inhibition tau will aggregate and cause cellular toxicity.25, 51 Furthermore our lab has 
shown that Hsc70 rapidly engages tau after microtubule destabilization and increases tau 
accumulation.52 This increase in tau accumulation could be due to CMA misprocessing 
of tau.53 Thus developing better tools that can divert tau away from Hsc70 and CMA by 
stimulating proteasomal degradation or macroautophagy will provide more effective 
treatments for stopping tau pathology. 
 
1.4 Tau Therapeutics 
Currently, there are not many effective treatments for people who suffer from 
tauopathies in particular AD. Current treatments for AD include acetylcholinesterase 
inhibitors, acetylcholine agonists, and glutamatergic antagonists.54 While these palliative 
medications help lessen the symptoms, they do not address the underlying cause of the 
disease or stop disease progression. Patients also spend around $177 to more than $400 
per month on medications.54 As a result more experimental strategies have been 
investigated to find better treatments for AD and other tauopathies. These current 
strategies include tau kinase inhibitors, tau immunotherapy, microtubule stabilizers, tau 
aggregation inhibitors, and small molecules targeting tau degradation.55 More specifically, 
kinase inhibitors have been used to reduce the hyperphosphorylation of tau and 
subsequent formation of neurofibrillary tangles. Inhibitors targeting the tau kinases GSK-
3β, PKC, Fyn (Src Kinase), and others have shown decreases in tau pathology.56-64 Some 
have been used in clinical trials and been well tolerated by patients. However many have 
concerns of potential debilitating side effects from inhibiting a kinase that phosphorylates 
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other clients besides tau.55 Another strategy that has been implemented to treat 
tauopathies is immunotherapy.61 Active and passive immunotherapy utilizing antibodies 
has been used to remove pathological forms of tau.60 Antibodies targeting specific 
phosphorylated tau species, tau aggregates, and tau oligomers have improved cognitive 
deficits in mice.38, 39, 65-68 However this strategy has shown safety concerns due to the fact 
that the phosphorylated tau species are not exclusive to the AD brain but also found in 
normal human brains.69 Therefore removing tau as seen in tau knockout mice can cause 
deleterious motor deficits, learning impairments and memory loss.70, 71 Another strategy 
used to treat tauopathies are tau aggregation inhibitors. There are several classes of tau 
aggregation inhibitors including the rhodanines, phenothiazines, carbocyanines, 
polyphenols, aminothienopyridazines, and anthraquinones.72-77 Anthraquinones such as 
emodin, daunorubicin and adriamycin target tau aggregates to prevent paired helical 
filament formation and cause PHF disassembly.77-79 However some tau aggregation 
inhibitors including the anthraquinones do not reduce monomeric soluble tau levels, which 
can potentially lead to the formation of toxic tau aggregates.80 Another relatively novel 
strategy to treat tauopathies is the use of microtubule stabilizing agents. Chemical 
compounds such as taxanes, epothilones, and pelorusides have been shown to stabilize 
microtubules in various models.81, 82 Two compounds in particular paclitaxel and 
epothilone D have been evaluated in animal models and have exhibited the most potential 
for clinical studies.81, 82 However many of the microtubule stabilizers may have frequent 
adverse side effects including increased cytotoxicity.55 
One last explorative strategy that has been implemented has been to control the 
protein quality control machinery to enhance tau degradation.  In particular, our group 
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and others have demonstrated that compounds targeting chaperones specifically heat 
shock proteins (Hsps) can reduce tau levels via the ubiquitin-proteasome system.83-86 Our 
lab has focused on these small molecules targeting Hsp70 family of proteins. The Hsp70s 
are 70 kilodaltons (kDa) molecular chaperones that help refold, degrade, and transport 
misfolded substrates/proteins such tau, α-synuclein, and TDP-43.87-90 Chaperones are 
upregulated and expressed when the cell undergoes an elevation in temperature or 
increase in stress.91 The Hsp70 family contains over 10 different isoforms which are 
located in various organelles in the cell and can be either stress-inducible or constitutively 
expressed.91 Our lab has shown that different isoforms of Hsp70, most notably the stress-
inducible form Hspa1A (Hsp72) and the constitutively expressed form Hspa8 (Hsc70), 
have differing effects on tau. Hsp72 reduces tau accumulation with the recruitment of the 
carboxyl terminus of the Hsc70-interacting protein (CHIP).92 CHIP acts as an E3 ubiquitin 
ligase and helps Hsp72 triage tau for proteasomal degradation.92 On the other hand 
Hsc70 preserves tau and slows its clearance possibly through CMA.92 While these 
isoforms have different effects on tau they and the rest of the Hsp70 family utilize 
adenosine triphosphate (ATP) to perform their functions. Most Hsp70s have three 
domains: an amino-terminal ATPase domain also known as the ATP-binding domain, the 
peptide or substrate binding domain and a carboxyl-terminal domain also known as the 
lid domain.91, 93  In the cellular environment Hsp70s first exist in an open confirmation or 
low affinity state with ATP bound in the ATPase domain.94 In this state Hsp70 substrates 
are allowed to become bound or unbound to Hsp70’s substrate binding domain. Once the 
Hsp70 is ready to perform its function on a bound substrate, it utilizes its intrinsic ATPase 
activity and recruits other heat shock proteins such as Hsp40/DnaJ also known as a 
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cochaperone to form a complex and help hydrolyze the ATP.94 This then changes the 
conformation of the Hsp70 to a closed or high affinity state with ADP bound.94 In addition 
the lid domain encloses the substrate for tight binding.94 The Hsp70 then carries out its 
function and it forms another complex with a cochaperone known as a nucleotide 
exchange factor (NEF) to help remove the ADP and then replace with ATP in order to 
repeat the cycle.94 The small molecule inhibitors targeting the Hsp70s specifically prevent 
the hydrolysis of ATP to ADP and the subsequent conformational change that allows the 
Hsp70s to carry out their functions. Many Hsp70 inhibitor scaffolds have been created 
that mimic ATP and act as a competitive inhibitor in the ATP pocket.95, 96 More common 
Hsp70 inhibitor scaffolds act as allosteric modulators and bind outside the ATP pocket.84, 
86, 97-101 Others have been suggested to directly interact with the DnaJ to prevent the 
stimulation of Hsp70’s ATPase activity.102 One last group of inhibitors have been shown 
to bind in the substrate binding domain and prevent interaction of the substrate with the 
Hsp70.103 In addition all of these compounds may be also able to prevent Hsc70 CMA 
facilitated tau aggregation, a potential effect which has yet to be investigated. More 
specifically compounds, YM-01, JG-98 and other members of the rhodacyanine family 
potently inhibit the Hsp70 family of proteins allosterically, which leads to rapid tau 
clearance through the proteasome.84, 104 Moreover our lab has demonstrated that these 
compounds do not damage microtubule dynamics while reducing abberant tau.104 This 
scaffold has also been modified successfully to improve potency and blood brain barrier 
permeability suggesting that this strategy could be useful in a clinical setting.104, 105 In 
addition, members of the phenothiazine family, which contains compounds such as 
methylene blue and azure C, also inhibit Hsp70 protein function, facilitate tau degradation 
11 
 
via the proteasome  and rescue memory deficits in tau transgenic mice.52, 106 Furthermore 
there is evidence that these compounds also can induce autophagic clearance of tau, 
highlighting the pleiotropic nature of this scaffold. Likewise inhibitors of another 
chaperone, heat shock protein 90 (Hsp90), have anti-tau activity.107-109 Like Hsp70 
inhibitors, these inhibitors also facilitate tau degradation via the proteasome. A number of 
clinical trials have been conducted with Hsp90 inhibitors for other diseases, in particular 
cancer, but the success with this approach has been modest due to pharmacological 
challenges.110-112  Additionally, autophagic clearance has been shown to be beneficial in 
attenuating tauopathies. Activating macroautophagy with rapamcyin was recently shown 
to have efficacy in a transgenic model of tauopathy, potentially ushering in a new avenue 
for tau expression reducing strategies aimed at autophagic pathways.113, 114 With this in 
mind, the  previous work showing that full-length monomeric tau is most efficiently cleared 
via the proteasome, while cleaved, oligomeric and aggregated tau species are more 
efficiently cleared via autophagy has elucidated the importance of developing drugs 
targeting tau degradation.25, 42, 43, 46, 51, 115  
 
1.5 Conclusion 
Overall, there are a variety of experimental strategies to treat tauopathies. Most 
have shown very adverse side effects and may not be as effective as current treatments.  
However our lab’s strategy of regulating the protein quality control machinery allows us 
to enhance or inhibit pathways shown to directly facilitate tau clearance or tau 
accumulation. Furthermore this strategy may better allow for combinatorial treatment 
12 
 
therapy which could be the next step in ameliorating the devastating pathology of 
tauopathies.  
 
1.6 References 
[1] Weingarten, M. D., Lockwood, A. H., Hwo, S. Y., and Kirschner, M. W. (1975) A protein 
factor essential for microtubule assembly, Proceedings of the National Academy 
of Sciences of the United States of America 72, 1858-1862. 
[2] Witman, G. B., Cleveland, D. W., Weingarten, M. D., and Kirschner, M. W. (1976) 
Tubulin requires tau for growth onto microtubule initiating sites, Proceedings of the 
National Academy of Sciences of the United States of America 73, 4070-4074. 
[3] Morris, M., Maeda, S., Vossel, K., and Mucke, L. (2011) The many faces of tau, Neuron 
70, 410-426. 
[4] Dixit, R., Ross, J. L., Goldman, Y. E., and Holzbaur, E. L. (2008) Differential regulation 
of dynein and kinesin motor proteins by tau, Science (New York, N.Y.) 319, 1086-
1089. 
[5] Ebneth, A., Godemann, R., Stamer, K., Illenberger, S., Trinczek, B., and Mandelkow, 
E. (1998) Overexpression of tau protein inhibits kinesin-dependent trafficking of 
vesicles, mitochondria, and endoplasmic reticulum: implications for Alzheimer's 
disease, The Journal of cell biology 143, 777-794. 
[6] Fulga, T. A., Elson-Schwab, I., Khurana, V., Steinhilb, M. L., Spires, T. L., Hyman, B. 
T., and Feany, M. B. (2007) Abnormal bundling and accumulation of F-actin 
mediates tau-induced neuronal degeneration in vivo, Nature cell biology 9, 139-
148. 
[7] Frost, B., Jacks, R. L., and Diamond, M. I. (2009) Propagation of tau misfolding from 
the outside to the inside of a cell, The Journal of biological chemistry 284, 12845-
12852. 
[8] Frost, B., and Diamond, M. I. (2010) Prion-like mechanisms in neurodegenerative 
diseases, Nature reviews. Neuroscience 11, 155-159. 
[9] Iba, M., Guo, J. L., McBride, J. D., Zhang, B., Trojanowski, J. Q., and Lee, V. M. (2013) 
Synthetic tau fibrils mediate transmission of neurofibrillary tangles in a transgenic 
mouse model of Alzheimer's-like tauopathy, The Journal of neuroscience : the 
official journal of the Society for Neuroscience 33, 1024-1037. 
[10] Wu, J. W., Herman, M., Liu, L., Simoes, S., Acker, C. M., Figueroa, H., Steinberg, J. 
I., Margittai, M., Kayed, R., Zurzolo, C., Di Paolo, G., and Duff, K. E. (2013) Small 
misfolded Tau species are internalized via bulk endocytosis and anterogradely and 
retrogradely transported in neurons, The Journal of biological chemistry 288, 1856-
1870. 
[11] Zempel, H., and Mandelkow, E. M. (2015) Tau missorting and spastin-induced 
microtubule disruption in neurodegeneration: Alzheimer Disease and Hereditary 
Spastic Paraplegia, Molecular neurodegeneration 10, 68. 
 
 
13 
 
[12] Miller, E. C., Teravskis, P. J., Dummer, B. W., Zhao, X., Huganir, R. L., and Liao, D. 
(2014) Tau phosphorylation and tau mislocalization mediate soluble Abeta 
oligomer-induced AMPA glutamate receptor signaling deficits, The European 
journal of neuroscience 39, 1214-1224. 
[13] Hoover, B. R., Reed, M. N., Su, J., Penrod, R. D., Kotilinek, L. A., Grant, M. K., 
Pitstick, R., Carlson, G. A., Lanier, L. M., Yuan, L. L., Ashe, K. H., and Liao, D. 
(2010) Tau mislocalization to dendritic spines mediates synaptic dysfunction 
independently of neurodegeneration, Neuron 68, 1067-1081. 
[14] Saman, S., Kim, W., Raya, M., Visnick, Y., Miro, S., Saman, S., Jackson, B., McKee, 
A. C., Alvarez, V. E., Lee, N. C., and Hall, G. F. (2012) Exosome-associated tau is 
secreted in tauopathy models and is selectively phosphorylated in cerebrospinal 
fluid in early Alzheimer disease, The Journal of biological chemistry 287, 3842-
3849. 
[15] Le, M. N., Kim, W., Lee, S., McKee, A. C., and Hall, G. F. (2012) Multiple mechanisms 
of extracellular tau spreading in a non-transgenic tauopathy model, American 
journal of neurodegenerative disease 1, 316-333. 
[16] Association, A. s. (2016) Alzheimer's & Dementia, Alzheimer's Association, Chicago, 
IL. 
[17] Martin, L., Latypova, X., and Terro, F. (2011) Post-translational modifications of tau 
protein: implications for Alzheimer's disease, Neurochemistry international 58, 
458-471. 
[18] Pittman, A. M., Fung, H. C., and de Silva, R. (2006) Untangling the tau gene 
association with neurodegenerative disorders, Human molecular genetics 15 Spec 
No 2, R188-195. 
[19] Maas, T., Eidenmuller, J., and Brandt, R. (2000) Interaction of tau with the neural 
membrane cortex is regulated by phosphorylation at sites that are modified in 
paired helical filaments, The Journal of biological chemistry 275, 15733-15740. 
[20] Cardenas-Aguayo Mdel, C., Gomez-Virgilio, L., DeRosa, S., and Meraz-Rios, M. A. 
(2014) The role of tau oligomers in the onset of Alzheimer's disease 
neuropathology, ACS chemical neuroscience 5, 1178-1191. 
[21] DeTure, M., Ko, L. W., Yen, S., Nacharaju, P., Easson, C., Lewis, J., van 
Slegtenhorst, M., Hutton, M., and Yen, S. H. (2000) Missense tau mutations 
identified in FTDP-17 have a small effect on tau-microtubule interactions, Brain 
research 853, 5-14. 
[22] Kiernan, P. T., Montenigro, P. H., Solomon, T. M., and McKee, A. C. (2015) Chronic 
traumatic encephalopathy: a neurodegenerative consequence of repetitive 
traumatic brain injury, Seminars in neurology 35, 20-28. 
[23] Greer, J. E., Hanell, A., McGinn, M. J., and Povlishock, J. T. (2013) Mild traumatic 
brain injury in the mouse induces axotomy primarily within the axon initial segment, 
Acta neuropathologica 126, 59-74. 
[24] Nixon, R. A., and Yang, D. S. (2011) Autophagy failure in Alzheimer's disease--
locating the primary defect, Neurobiology of disease 43, 38-45. 
[25] Wang, Y., Martinez-Vicente, M., Kruger, U., Kaushik, S., Wong, E., Mandelkow, E. 
M., Cuervo, A. M., and Mandelkow, E. (2010) Synergy and antagonism of 
macroautophagy and chaperone-mediated autophagy in a cell model of 
pathological tau aggregation, Autophagy 6, 182-183. 
14 
 
[26] Bence, N. F., Sampat, R. M., and Kopito, R. R. (2001) Impairment of the ubiquitin-
proteasome system by protein aggregation, Science (New York, N.Y.) 292, 1552-
1555. 
[27] von Bergen, M., Friedhoff, P., Biernat, J., Heberle, J., Mandelkow, E. M., and 
Mandelkow, E. (2000) Assembly of tau protein into Alzheimer paired helical 
filaments depends on a local sequence motif ((306)VQIVYK(311)) forming beta 
structure, Proceedings of the National Academy of Sciences of the United States 
of America 97, 5129-5134. 
[28] Friedhoff, P., von Bergen, M., Mandelkow, E. M., and Mandelkow, E. (2000) Structure 
of tau protein and assembly into paired helical filaments, Biochim. Biophys. Acta 
1502, 122-132. 
[29] Meraz-Rios, M. A., Lira-De Leon, K. I., Campos-Pena, V., De Anda-Hernandez, M. 
A., and Mena-Lopez, R. (2010) Tau oligomers and aggregation in Alzheimer's 
disease, Journal of neurochemistry 112, 1353-1367. 
[30] Kuret, J., Chirita, C. N., Congdon, E. E., Kannanayakal, T., Li, G., Necula, M., Yin, 
H., and Zhong, Q. (2005) Pathways of tau fibrillization, Biochim. Biophys. Acta 
1739, 167-178. 
[31] Walker, S., Ullman, O., and Stultz, C. M. (2012) Using intramolecular disulfide bonds 
in tau protein to deduce structural features of aggregation-resistant conformations, 
The Journal of biological chemistry 287, 9591-9600. 
[32] Di Noto, L., DeTure, M. A., and Purich, D. L. (1999) Disulfide-cross-linked tau and 
MAP2 homodimers readily promote microtubule assembly, Molecular cell biology 
research communications : MCBRC 2, 71-76. 
[33] Inouye, H., Sharma, D., Goux, W. J., and Kirschner, D. A. (2006) Structure of core 
domain of fibril-forming PHF/Tau fragments, Biophys. J. 90, 1774-1789. 
[34] Tabaton, M., Mandybur, T. I., Perry, G., Onorato, M., Autilio-Gambetti, L., and 
Gambetti, P. (1989) The widespread alteration of neurites in Alzheimer's disease 
may be unrelated to amyloid deposition, Annals of neurology 26, 771-778. 
[35] Castellani, R. J., Nunomura, A., Lee, H. G., Perry, G., and Smith, M. A. (2008) 
Phosphorylated tau: toxic, protective, or none of the above, Journal of Alzheimer's 
disease : JAD 14, 377-383. 
[36] Iqbal, K., Alonso Adel, C., and Grundke-Iqbal, I. (2008) Cytosolic abnormally 
hyperphosphorylated tau but not paired helical filaments sequester normal MAPs 
and inhibit microtubule assembly, Journal of Alzheimer's disease : JAD 14, 365-
370. 
[37] Gerson, J. E., and Kayed, R. (2013) Formation and propagation of tau oligomeric 
seeds, Frontiers in neurology 4, 93. 
[38] Castillo-Carranza, D. L., Sengupta, U., Guerrero-Munoz, M. J., Lasagna-Reeves, C. 
A., Gerson, J. E., Singh, G., Estes, D. M., Barrett, A. D., Dineley, K. T., Jackson, 
G. R., and Kayed, R. (2014) Passive immunization with Tau oligomer monoclonal 
antibody reverses tauopathy phenotypes without affecting hyperphosphorylated 
neurofibrillary tangles, The Journal of neuroscience : the official journal of the 
Society for Neuroscience 34, 4260-4272. 
 
 
15 
 
[39] Castillo-Carranza, D. L., Gerson, J. E., Sengupta, U., Guerrero-Munoz, M. J., 
Lasagna-Reeves, C. A., and Kayed, R. (2014) Specific targeting of tau oligomers 
in Htau mice prevents cognitive impairment and tau toxicity following injection with 
brain-derived tau oligomeric seeds, Journal of Alzheimer's disease : JAD 40 Suppl 
1, S97-s111. 
[40] Selenica, M. L., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., 
Gordon, M. N., and Morgan, D. (2013) Amyloid oligomers exacerbate tau 
pathology in a mouse model of tauopathy, Neuro-degenerative diseases 11, 165-
181. 
[41] Glickman, M. H., and Ciechanover, A. (2002) The ubiquitin-proteasome proteolytic 
pathway: destruction for the sake of construction, Physiological reviews 82, 373-
428. 
[42] Lee, M. J., Lee, J. H., and Rubinsztein, D. C. (2013) Tau degradation: the ubiquitin-
proteasome system versus the autophagy-lysosome system, Prog. Neurobiol. 
105, 49-59. 
[43] Dolan, P. J., and Johnson, G. V. (2010) A caspase cleaved form of tau is 
preferentially degraded through the autophagy pathway, J. Biol. Chem. 285, 
21978-21987. 
[44] Do, T. D., Economou, N. J., Chamas, A., Buratto, S. K., Shea, J. E., and Bowers, M. 
T. (2014) Interactions between amyloid-beta and Tau fragments promote aberrant 
aggregates: implications for amyloid toxicity, J. Phys. Chem. B 118, 11220-11230. 
[45] Wang, Y., Martinez-Vicente, M., Kruger, U., Kaushik, S., Wong, E., Mandelkow, E. 
M., Cuervo, A. M., and Mandelkow, E. (2009) Tau fragmentation, aggregation and 
clearance: the dual role of lysosomal processing, Human molecular genetics 18, 
4153-4170. 
[46] Schaeffer, V., Lavenir, I., Ozcelik, S., Tolnay, M., Winkler, D. T., and Goedert, M. 
(2012) Stimulation of autophagy reduces neurodegeneration in a mouse model of 
human tauopathy, Brain : a journal of neurology 135, 2169-2177. 
[47] Yamaguchi, O., and Otsu, K. (2012) Role of autophagy in aging, J. Cardiovasc. 
Pharmacol. 60, 242-247. 
[48] Dong, H., and Czaja, M. J. (2011) Regulation of lipid droplets by autophagy, Trends 
in endocrinology and metabolism: TEM 22, 234-240. 
[49] Chiang, H. L., Terlecky, S. R., Plant, C. P., and Dice, J. F. (1989) A role for a 70-
kilodalton heat shock protein in lysosomal degradation of intracellular proteins, 
Science (New York, N.Y.) 246, 382-385. 
[50] Kenessey, A., Nacharaju, P., Ko, L. W., and Yen, S. H. (1997) Degradation of tau by 
lysosomal enzyme cathepsin D: implication for Alzheimer neurofibrillary 
degeneration, Journal of neurochemistry 69, 2026-2038. 
[51] Wang, Y., Kruger, U., Mandelkow, E., and Mandelkow, E. M. (2010) Generation of 
tau aggregates and clearance by autophagy in an inducible cell model of 
tauopathy, Neuro-degenerative diseases 7, 103-107. 
[52] Jinwal, U. K., O'Leary, J. C., 3rd, Borysov, S. I., Jones, J. R., Li, Q., Koren, J., 3rd, 
Abisambra, J. F., Vestal, G. D., Lawson, L. Y., Johnson, A. G., Blair, L. J., Jin, Y., 
Miyata, Y., Gestwicki, J. E., and Dickey, C. A. (2010) Hsc70 rapidly engages tau 
after microtubule destabilization, J. Biol. Chem. 285, 16798-16805. 
16 
 
[53] Cuervo, A. M., and Wong, E. (2014) Chaperone-mediated autophagy: roles in 
disease and aging, Cell research 24, 92-104. 
[54] Media, H. (2016) Find the Best Medications for Alzheimer's Disease, Healthline 
Media. 
[55] Gerson, J. E., Castillo-Carranza, D. L., and Kayed, R. (2014) Advances in 
Therapeutics for Neurodegenerative Tauopathies: Moving toward the Specific 
Targeting of the Most Toxic Tau Species, ACS Chem. Neurosci. 5, 752-769. 
[56] Caccamo, A., Oddo, S., Tran, L. X., and LaFerla, F. M. (2007) Lithium reduces tau 
phosphorylation but not A beta or working memory deficits in a transgenic model 
with both plaques and tangles, The American journal of pathology 170, 1669-1675. 
[57] Sereno, L., Coma, M., Rodriguez, M., Sanchez-Ferrer, P., Sanchez, M. B., Gich, I., 
Agullo, J. M., Perez, M., Avila, J., Guardia-Laguarta, C., Clarimon, J., Lleo, A., and 
Gomez-Isla, T. (2009) A novel GSK-3beta inhibitor reduces Alzheimer's pathology 
and rescues neuronal loss in vivo, Neurobiology of disease 35, 359-367. 
[58] Noble, W., Planel, E., Zehr, C., Olm, V., Meyerson, J., Suleman, F., Gaynor, K., 
Wang, L., LaFrancois, J., Feinstein, B., Burns, M., Krishnamurthy, P., Wen, Y., 
Bhat, R., Lewis, J., Dickson, D., and Duff, K. (2005) Inhibition of glycogen synthase 
kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo, 
Proceedings of the National Academy of Sciences of the United States of America 
102, 6990-6995. 
[59] Smith, B., Medda, F., Gokhale, V., Dunckley, T., and Hulme, C. (2012) Recent 
advances in the design, synthesis, and biological evaluation of selective DYRK1A 
inhibitors: a new avenue for a disease modifying treatment of Alzheimer's?, ACS 
chemical neuroscience 3, 857-872. 
[60] Frost, D., Meechoovet, B., Wang, T., Gately, S., Giorgetti, M., Shcherbakova, I., and 
Dunckley, T. (2011) beta-carboline compounds, including harmine, inhibit 
DYRK1A and tau phosphorylation at multiple Alzheimer's disease-related sites, 
PloS one 6, e19264. 
[61] Piette, F., Belmin, J., Vincent, H., Schmidt, N., Pariel, S., Verny, M., Marquis, C., 
Mely, J., Hugonot-Diener, L., Kinet, J. P., Dubreuil, P., Moussy, A., and Hermine, 
O. (2011) Masitinib as an adjunct therapy for mild-to-moderate Alzheimer's 
disease: a randomised, placebo-controlled phase 2 trial, Alzheimers Res. Ther. 3, 
16. 
[62] Nygaard, H. B., van Dyck, C. H., and Strittmatter, S. M. (2014) Fyn kinase inhibition 
as a novel therapy for Alzheimer's disease, Alzheimers Res. Ther. 6, 8. 
[63] Bhaskar, K., Hobbs, G. A., Yen, S. H., and Lee, G. (2010) Tyrosine phosphorylation 
of tau accompanies disease progression in transgenic mouse models of tauopathy, 
Neuropathology and applied neurobiology 36, 462-477. 
[64] Selenica, M. L., Davtyan, H., Housley, S. B., Blair, L. J., Gillies, A., Nordhues, B. A., 
Zhang, B., Liu, J., Gestwicki, J. E., Lee, D. C., Gordon, M. N., Morgan, D., and 
Dickey, C. A. (2014) Epitope analysis following active immunization with tau 
proteins reveals immunogens implicated in tau pathogenesis, Journal of 
neuroinflammation 11, 152. 
 
 
17 
 
[65] Lewis, J., McGowan, E., Rockwood, J., Melrose, H., Nacharaju, P., Van Slegtenhorst, 
M., Gwinn-Hardy, K., Paul Murphy, M., Baker, M., Yu, X., Duff, K., Hardy, J., Corral, 
A., Lin, W. L., Yen, S. H., Dickson, D. W., Davies, P., and Hutton, M. (2000) 
Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice 
expressing mutant (P301L) tau protein, Nature genetics 25, 402-405. 
[66] Asuni, A. A., Boutajangout, A., Quartermain, D., and Sigurdsson, E. M. (2007) 
Immunotherapy targeting pathological tau conformers in a tangle mouse model 
reduces brain pathology with associated functional improvements, The Journal of 
neuroscience : the official journal of the Society for Neuroscience 27, 9115-9129. 
[67] Troquier, L., Caillierez, R., Burnouf, S., Fernandez-Gomez, F. J., Grosjean, M. E., 
Zommer, N., Sergeant, N., Schraen-Maschke, S., Blum, D., and Buee, L. (2012) 
Targeting phospho-Ser422 by active Tau Immunotherapy in the THYTau22 mouse 
model: a suitable therapeutic approach, Current Alzheimer research 9, 397-405. 
[68] Yanamandra, K., Kfoury, N., Jiang, H., Mahan, T. E., Ma, S., Maloney, S. E., 
Wozniak, D. F., Diamond, M. I., and Holtzman, D. M. (2013) Anti-tau antibodies 
that block tau aggregate seeding in vitro markedly decrease pathology and 
improve cognition in vivo, Neuron 80, 402-414. 
[69] Rozenstein-Tsalkovich, L., Grigoriadis, N., Lourbopoulos, A., Nousiopoulou, E., 
Kassis, I., Abramsky, O., Karussis, D., and Rosenmann, H. (2013) Repeated 
immunization of mice with phosphorylated-tau peptides causes 
neuroinflammation, Experimental neurology 248, 451-456. 
[70] Lopes, S., Lopes, A., Pinto, V., Guimaraes, M. R., Sardinha, V. M., Duarte-Silva, S., 
Pinheiro, S., Pizarro, J., Oliveira, J. F., Sousa, N., Leite-Almeida, H., and 
Sotiropoulos, I. (2016) Absence of Tau triggers age-dependent sciatic nerve 
morphofunctional deficits and motor impairment, Aging cell 15, 208-216. 
[71] Ma, Q. L., Zuo, X., Yang, F., Ubeda, O. J., Gant, D. J., Alaverdyan, M., Kiosea, N. 
C., Nazari, S., Chen, P. P., Nothias, F., Chan, P., Teng, E., Frautschy, S. A., and 
Cole, G. M. (2014) Loss of MAP function leads to hippocampal synapse loss and 
deficits in the Morris Water Maze with aging, The Journal of neuroscience : the 
official journal of the Society for Neuroscience 34, 7124-7136. 
[72] Ballatore, C., Crowe, A., Piscitelli, F., James, M., Lou, K., Rossidivito, G., Yao, Y., 
Trojanowski, J. Q., Lee, V. M., Brunden, K. R., and Smith, A. B., 3rd. (2012) 
Aminothienopyridazine inhibitors of tau aggregation: evaluation of structure-
activity relationship leads to selection of candidates with desirable in vivo 
properties, Bioorg. Med. Chem. 20, 4451-4461. 
[73] Crowe, A., James, M. J., Lee, V. M., Smith, A. B., 3rd, Trojanowski, J. Q., Ballatore, 
C., and Brunden, K. R. (2013) Aminothienopyridazines and methylene blue affect 
Tau fibrillization via cysteine oxidation, The Journal of biological chemistry 288, 
11024-11037. 
[74] Daccache, A., Lion, C., Sibille, N., Gerard, M., Slomianny, C., Lippens, G., and 
Cotelle, P. (2011) Oleuropein and derivatives from olives as Tau aggregation 
inhibitors, Neurochemistry international 58, 700-707. 
[75] Wischik, C. M., Edwards, P. C., Lai, R. Y., Roth, M., and Harrington, C. R. (1996) 
Selective inhibition of Alzheimer disease-like tau aggregation by phenothiazines, 
Proceedings of the National Academy of Sciences of the United States of America 
93, 11213-11218. 
18 
 
[76] Congdon, E. E., Necula, M., Blackstone, R. D., and Kuret, J. (2007) Potency of a tau 
fibrillization inhibitor is influenced by its aggregation state, Archives of biochemistry 
and biophysics 465, 127-135. 
[77] Pickhardt, M., Gazova, Z., von Bergen, M., Khlistunova, I., Wang, Y., Hascher, A., 
Mandelkow, E. M., Biernat, J., and Mandelkow, E. (2005) Anthraquinones inhibit 
tau aggregation and dissolve Alzheimer's paired helical filaments in vitro and in 
cells, The Journal of biological chemistry 280, 3628-3635. 
[78] Duff, K., Kuret, J., and Congdon, E. E. (2010) Disaggregation of tau as a therapeutic 
approach to tauopathies, Current Alzheimer research 7, 235-240. 
[79] Johnson, R. L., Huang, W., Huang, R., Crowe, A., Ballatore, C., Trojanowski, J. Q., 
Brunden, K. R., and Lee, V. M. Y. (2010) High Throughput Screening for Small 
Molecule Inhibitors of Heparin-induced Tau Fibril Formation, In Probe Reports from 
the NIH Molecular Libraries Program, National Center for Biotechnology 
Information (US), Bethesda (MD). 
[80] Stamer, K., Vogel, R., Thies, E., Mandelkow, E., and Mandelkow, E. M. (2002) Tau 
blocks traffic of organelles, neurofilaments, and APP vesicles in neurons and 
enhances oxidative stress, The Journal of cell biology 156, 1051-1063. 
[81] Ballatore, C., Brunden, K. R., Huryn, D. M., Trojanowski, J. Q., Lee, V. M., and Smith, 
A. B., 3rd. (2012) Microtubule stabilizing agents as potential treatment for 
Alzheimer's disease and related neurodegenerative tauopathies, Journal of 
medicinal chemistry 55, 8979-8996. 
[82] Brunden, K. R., Trojanowski, J. Q., Smith, A. B., 3rd, Lee, V. M., and Ballatore, C. 
(2014) Microtubule-stabilizing agents as potential therapeutics for 
neurodegenerative disease, Bioorganic & medicinal chemistry 22, 5040-5049. 
[83] Miyata, Y., Li, X., Lee, H. F., Jinwal, U. K., Srinivasan, S. R., Seguin, S. P., Young, 
Z. T., Brodsky, J. L., Dickey, C. A., Sun, D., and Gestwicki, J. E. (2013) Synthesis 
and initial evaluation of YM-08, a blood-brain barrier permeable derivative of the 
heat shock protein 70 (Hsp70) inhibitor MKT-077, which reduces tau levels, ACS 
Chem. Neurosci. 4, 930-939. 
[84] Abisambra, J., Jinwal, U. K., Miyata, Y., Rogers, J., Blair, L., Li, X., Seguin, S. P., 
Wang, L., Jin, Y., Bacon, J., Brady, S., Cockman, M., Guidi, C., Zhang, J., Koren, 
J., Young, Z. T., Atkins, C. A., Zhang, B., Lawson, L. Y., Weeber, E. J., Brodsky, 
J. L., Gestwicki, J. E., and Dickey, C. A. (2013) Allosteric heat shock protein 70 
inhibitors rapidly rescue synaptic plasticity deficits by reducing aberrant tau, Biol. 
Psychiatry 74, 367-374. 
[85] Jinwal, U. K., Koren, J., O'Leary, J. C., Jones, J. R., Abisambra, J. F., and Dickey, C. 
A. (2010) Hsp70 ATPase Modulators as Therapeutics for Alzheimer's and other 
Neurodegenerative Diseases, Mol Cell Pharmacol 2, 43-46. 
[86] Jinwal, U. K., Miyata, Y., Koren, J., 3rd, Jones, J. R., Trotter, J. H., Chang, L., 
O'Leary, J., Morgan, D., Lee, D. C., Shults, C. L., Rousaki, A., Weeber, E. J., 
Zuiderweg, E. R., Gestwicki, J. E., and Dickey, C. A. (2009) Chemical manipulation 
of hsp70 ATPase activity regulates tau stability, J. Neurosci. 29, 12079-12088. 
[87] Thompson, A. D., Scaglione, K. M., Prensner, J., Gillies, A. T., Chinnaiyan, A., 
Paulson, H. L., Jinwal, U. K., Dickey, C. A., and Gestwicki, J. E. (2012) Analysis of 
the tau-associated proteome reveals that exchange of Hsp70 for Hsp90 is involved 
in tau degradation, ACS chemical biology 7, 1677-1686. 
19 
 
[88] Cuervo, A. M., Stefanis, L., Fredenburg, R., Lansbury, P. T., and Sulzer, D. (2004) 
Impaired degradation of mutant alpha-synuclein by chaperone-mediated 
autophagy, Science (New York, N.Y.) 305, 1292-1295. 
[89] Auluck, P. K., Chan, H. Y., Trojanowski, J. Q., Lee, V. M., and Bonini, N. M. (2002) 
Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for 
Parkinson's disease, Science (New York, N.Y.) 295, 865-868. 
[90] Udan-Johns, M., Bengoechea, R., Bell, S., Shao, J., Diamond, M. I., True, H. L., 
Weihl, C. C., and Baloh, R. H. (2014) Prion-like nuclear aggregation of TDP-43 
during heat shock is regulated by HSP40/70 chaperones, Human molecular 
genetics 23, 157-170. 
[91] Mayer, M. P., and Bukau, B. (2005) Hsp70 chaperones: cellular functions and 
molecular mechanism, Cellular and molecular life sciences : CMLS 62, 670-684. 
[92] Jinwal, U. K., Akoury, E., Abisambra, J. F., O'Leary, J. C., 3rd, Thompson, A. D., 
Blair, L. J., Jin, Y., Bacon, J., Nordhues, B. A., Cockman, M., Zhang, J., Li, P., 
Zhang, B., Borysov, S., Uversky, V. N., Biernat, J., Mandelkow, E., Gestwicki, J. 
E., Zweckstetter, M., and Dickey, C. A. (2013) Imbalance of Hsp70 family variants 
fosters tau accumulation, FASEB J. 27, 1450-1459. 
[93] Tsukahara, F., Yoshioka, T., and Muraki, T. (2000) Molecular and functional 
characterization of HSC54, a novel variant of human heat-shock cognate protein 
70, Mol. Pharmacol. 58, 1257-1263. 
[94] Sullivan, C. S., and Pipas, J. M. (2002) T antigens of simian virus 40: molecular 
chaperones for viral replication and tumorigenesis, Microbiology and molecular 
biology reviews : MMBR 66, 179-202. 
[95] Williamson, D. S., Borgognoni, J., Clay, A., Daniels, Z., Dokurno, P., Drysdale, M. J., 
Foloppe, N., Francis, G. L., Graham, C. J., Howes, R., Macias, A. T., Murray, J. 
B., Parsons, R., Shaw, T., Surgenor, A. E., Terry, L., Wang, Y., Wood, M., and 
Massey, A. J. (2009) Novel adenosine-derived inhibitors of 70 kDa heat shock 
protein, discovered through structure-based design, Journal of medicinal 
chemistry 52, 1510-1513. 
[96] Massey, A. J., Williamson, D. S., Browne, H., Murray, J. B., Dokurno, P., Shaw, T., 
Macias, A. T., Daniels, Z., Geoffroy, S., Dopson, M., Lavan, P., Matassova, N., 
Francis, G. L., Graham, C. J., Parsons, R., Wang, Y., Padfield, A., Comer, M., 
Drysdale, M. J., and Wood, M. (2010) A novel, small molecule inhibitor of 
Hsc70/Hsp70 potentiates Hsp90 inhibitor induced apoptosis in HCT116 colon 
carcinoma cells, Cancer chemotherapy and pharmacology 66, 535-545. 
[97] Chang, L., Bertelsen, E. B., Wisen, S., Larsen, E. M., Zuiderweg, E. R., and 
Gestwicki, J. E. (2008) High-throughput screen for small molecules that modulate 
the ATPase activity of the molecular chaperone DnaK, Anal. Biochem. 372, 167-
176. 
[98] Miyata, Y., Rauch, J. N., Jinwal, U. K., Thompson, A. D., Srinivasan, S., Dickey, C. 
A., and Gestwicki, J. E. (2012) Cysteine reactivity distinguishes redox sensing by 
the heat-inducible and constitutive forms of heat shock protein 70, Chemistry & 
biology 19, 1391-1399. 
 
 
20 
 
[99] Li, X., Srinivasan, S. R., Connarn, J., Ahmad, A., Young, Z. T., Kabza, A. M., 
Zuiderweg, E. R., Sun, D., and Gestwicki, J. E. (2013) Analogs of the Allosteric 
Heat Shock Protein 70 (Hsp70) Inhibitor, MKT-077, as Anti-Cancer Agents, ACS 
Med Chem Lett 4. 
[100] Kang, Y., Taldone, T., Patel, H. J., Patel, P. D., Rodina, A., Gozman, A., Maharaj, 
R., Clement, C. C., Patel, M. R., Brodsky, J. L., Young, J. C., and Chiosis, G. 
(2014) Heat shock protein 70 inhibitors. 1. 2,5'-thiodipyrimidine and 5-
(phenylthio)pyrimidine acrylamides as irreversible binders to an allosteric site on 
heat shock protein 70, Journal of medicinal chemistry 57, 1188-1207. 
[101] Taldone, T., Kang, Y., Patel, H. J., Patel, M. R., Patel, P. D., Rodina, A., Patel, Y., 
Gozman, A., Maharaj, R., Clement, C. C., Lu, A., Young, J. C., and Chiosis, G. 
(2014) Heat shock protein 70 inhibitors. 2. 2,5'-thiodipyrimidines, 5-
(phenylthio)pyrimidines, 2-(pyridin-3-ylthio)pyrimidines, and 3-
(phenylthio)pyridines as reversible binders to an allosteric site on heat shock 
protein 70, Journal of medicinal chemistry 57, 1208-1224. 
[102] Cassel, J. A., Ilyin, S., McDonnell, M. E., and Reitz, A. B. (2012) Novel inhibitors of 
heat shock protein Hsp70-mediated luciferase refolding that bind to DnaJ, 
Bioorganic & medicinal chemistry 20, 3609-3614. 
[103] Leu, J. I., Pimkina, J., Frank, A., Murphy, M. E., and George, D. L. (2009) A small 
molecule inhibitor of inducible heat shock protein 70, Molecular cell 36, 15-27. 
[104] Fontaine, S. N., Martin, M. D., Akoury, E., Assimon, V. A., Borysov, S., Nordhues, 
B. A., Sabbagh, J. J., Cockman, M., Gestwicki, J. E., Zweckstetter, M., and Dickey, 
C. A. (2015) The active Hsc70/tau complex can be exploited to enhance tau 
turnover without damaging microtubule dynamics, Human molecular genetics 24, 
3971-3981. 
[105] Miyata, Y., Li, X., Lee, H. F., Jinwal, U. K., Srinivasan, S. R., Seguin, S. P., Young, 
Z. T., Brodsky, J. L., Dickey, C. A., Sun, D., and Gestwicki, J. E. (2013) Synthesis 
and initial evaluation of YM-08, a blood-brain barrier permeable derivative of the 
heat shock protein 70 (Hsp70) inhibitor MKT-077, which reduces tau levels, ACS 
chemical neuroscience 4, 930-939. 
[106] O'Leary, J. C., 3rd, Li, Q., Marinec, P., Blair, L. J., Congdon, E. E., Johnson, A. G., 
Jinwal, U. K., Koren, J., 3rd, Jones, J. R., Kraft, C., Peters, M., Abisambra, J. F., 
Duff, K. E., Weeber, E. J., Gestwicki, J. E., and Dickey, C. A. (2010) Phenothiazine-
mediated rescue of cognition in tau transgenic mice requires neuroprotection and 
reduced soluble tau burden, Mol. Neurodegener. 5, 45. 
[107] Congdon, E. E., Wu, J. W., Myeku, N., Figueroa, Y. H., Herman, M., Marinec, P. S., 
Gestwicki, J. E., Dickey, C. A., Yu, W. H., and Duff, K. E. (2012) Methylthioninium 
chloride (methylene blue) induces autophagy and attenuates tauopathy in vitro and 
in vivo, Autophagy 8, 609-622. 
[108] Dickey, C. A., Kamal, A., Lundgren, K., Klosak, N., Bailey, R. M., Dunmore, J., Ash, 
P., Shoraka, S., Zlatkovic, J., Eckman, C. B., Patterson, C., Dickson, D. W., 
Nahman, N. S., Jr., Hutton, M., Burrows, F., and Petrucelli, L. (2007) The high-
affinity HSP90-CHIP complex recognizes and selectively degrades 
phosphorylated tau client proteins, The Journal of clinical investigation 117, 648-
658. 
21 
 
[109] Luo, W., Dou, F., Rodina, A., Chip, S., Kim, J., Zhao, Q., Moulick, K., Aguirre, J., 
Wu, N., Greengard, P., and Chiosis, G. (2007) Roles of heat-shock protein 90 in 
maintaining and facilitating the neurodegenerative phenotype in tauopathies, 
Proceedings of the National Academy of Sciences of the United States of America 
104, 9511-9516. 
[110] Erlichman, C. (2009) Tanespimycin: the opportunities and challenges of targeting 
heat shock protein 90, Expert Opin. Investig. Drugs 18, 861-868. 
[111] Sidera, K., and Patsavoudi, E. (2014) HSP90 inhibitors: current development and 
potential in cancer therapy, Recent Pat. Anticancer Drug Discov. 9, 1-20. 
[112] Jhaveri, K., Ochiana, S. O., Dunphy, M. P., Gerecitano, J. F., Corben, A. D., Peter, 
R. I., Janjigian, Y. Y., Gomes-DaGama, E. M., Koren, J., 3rd, Modi, S., and Chiosis, 
G. (2014) Heat shock protein 90 inhibitors in the treatment of cancer: current status 
and future directions, Expert Opin. Investig. Drugs 23, 611-628. 
[113] Majumder, S., Richardson, A., Strong, R., and Oddo, S. (2011) Inducing autophagy 
by rapamycin before, but not after, the formation of plaques and tangles 
ameliorates cognitive deficits, PloS one 6, e25416. 
[114] Caccamo, A., De Pinto, V., Messina, A., Branca, C., and Oddo, S. (2014) Genetic 
reduction of mammalian target of rapamycin ameliorates Alzheimer's disease-like 
cognitive and pathological deficits by restoring hippocampal gene expression 
signature, J. Neurosci. 34, 7988-7998. 
[115] Rubinsztein, D. C. (2006) The roles of intracellular protein-degradation pathways in 
neurodegeneration, Nature 443, 780-786. 
22 
 
 
 
 
 
 
CHAPTER TWO: 
 
SYNTHESIS, STEREOCHEMICAL ANALYSIS, AND DERIVATIZATION OF 
MYRICANOL PROVIDE NEW PROBES THAT PROMOTE AUTOPHAGIC TAU 
CLEARANCE  
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2.1 Abstract 
 We previously discovered that one specific scalemic preparation of myricanol (1), a 
constituent of Myrica cerifera (bayberry/southern wax myrtle) root bark could lower the 
levels of the microtubule associated protein tau (MAPT). The significance is that tau 
accumulates in a number of neurodegenerative diseases, the most common being 
Alzheimer’s disease (AD). Herein a new synthetic route to prepare myricanol using a 
suitable boronic acid pinacol ester intermediate is reported. An X-ray crystal structure of 
the isolated myricanol (1) was obtained and showed a co-crystal consisting of (+)-aR,11S-
myricanol (2) and (-)-aS,11R-myricanol (3) co-formers. Surprisingly, 3, obtained from 
chiral separation from 1, reduced tau levels in both cultured cells and ex vivo brain slices 
from a mouse model of tauopathy at reasonable mid to low µM concentration while 2 did 
not. SILAC proteomics and cell assays revealed that 3 promoted tau degradation through 
an autophagic mechanism, which was in contrast to other tau-reducing compounds 
previously identified by our group. During the course of structure-activity relationship 
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(SAR) development we prepared compound 13 by acid-catalyzed dehydration of 1. 13 
had undergone an unexpected structural rearrangement through the isomyricanol 
substitution pattern (e.g. 16) as verified by X-ray structural analysis. Compound 13 
displayed robust tau-reducing activity and, importantly, its enantiomers reduced tau levels 
similarly. Therefore, the semisynthetic analog 13 provides a foundation for further 
development as an anti-tau activity agent without SAR being based on chirality.  
 
2.2 Introduction 
Aberrant accumulation of the microtubule associated protein tau is implicated in 
~20 neurodegenerative disorders collectively termed tauopathies, including chronic 
traumatic encephalopathy (CTE), Alzheimer’s disease (AD), frontal temporal dementia 
linked to chromosome 17 (FTDP-17), Parkinson’s disease and Pick’s disease.1, 2 Some 
of these diseases can be caused by mutations in the MAPT gene which result in amino 
acid substitution in critical microtubule-interacting domains.3  Tauopathies may also result 
from a cascade of pathological events, such as amyloid β aggregation, leading to 
microtubule destabilization and the hyperphosphorylation of tau.4 Tau 
hyperphosphorylation induces the formation of toxic tau-containing aggregates, resulting 
in neuronal loss causing cognitive and motor deficits.5, 6  
A number of strategies have been explored to treat tauopathies by targeting 
mechanisms of tau biology directly. Kinase inhibitors have been used to reduce the 
hyperphosphorylation of tau and subsequent formation of neurofibrillary tangles. 
Inhibitors of known tau kinases such as glycogen synthase kinase 3β (GSK-3β), protein 
kinase C (PKC), Fyn (Src Kinase), and others have shown decreases in tau pathology.7 
This strategy has had mixed results in the clinic, but none of these inhibitors have been 
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approved for practical use.8, 9  Immunotherapy is another strategy that is being extensively 
investigated to treat tauopathies. Both active and passive immunotherapy approaches 
can successfully remove pathological forms of tau in mouse models,7 but passive 
immunization holds more promise in the clinic because of its higher selectivity for discreet 
tau species and greater administrative control in the event of autoimmune reactions. 
However, even this strategy has some safety concerns since phosphorylated tau species 
are found in normal as well as AD brains.10 Nevertheless, clinical trials using passive 
immunization with antibodies targeting tau are ongoing. Another strategy being explored 
to treat tauopathies is inhibition of tau aggregation. A number of compounds have been 
identified that can prevent paired helical filament (PHF) formation and cause PHF 
disassembly.7 These compounds have also shown efficacy in mouse models of 
tauopathy.11, 12 Replacing tau function with microtubule stabilizing compounds has also 
shown efficacy in mouse models of tauopathy, and this strategy is currently in the early 
stages of clinical development.13 But currently there are no approved treatments for the 
tauopathies that target tau biology directly.7 
The strategy that our lab has pursued over the past several years is distinct from 
these other mechanisms in that we are trying to harness the protein quality control 
machinery to promote tau degradation.14, 15  Molecules targeting heat shock proteins 
(Hsp), ubiquitin ligase complexes, and deubiquitinating enzymes have been effective at 
inducing proteasomal degradation of tau.16 For example, YM-01 and other members of 
the rhodacyanine family potently inhibit the Hsp70 family of proteins, which concomitantly 
leads to rapid tau clearance through the proteasome. This scaffold has also been 
modified successfully to improve blood brain barrier permeability, suggesting that it could 
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be useful therapeutically.17 Inhibitors of another chaperone, Hsp90, also have anti-tau 
activity.18, 19 Like Hsp70 inhibitors, these also facilitate tau degradation via the 
proteasome. A number of clinical trials have been conducted with Hsp90 inhibitors for 
other diseases, in particular cancer, but the success with this approach has been modest 
due to pharmacological challenges.20-22 Members of the phenothiazine family, which 
contains compounds such as methylene blue and azure C, also inhibit Hsp70 protein 
function, facilitate tau degradation via the proteasome15 and rescue memory deficits in 
tau transgenic mice;23 however there is evidence that these compounds also can induce 
autophagic clearance of tau24. Recent work has shown that full-length monomeric tau is 
most efficiently cleared via the proteasome,16, 25, 26 while cleaved, oligomeric and 
aggregated tau species that are more closely tied to toxicity are more efficiently cleared 
via autophagy.16 In fact, autophagic clearance has been shown to be most beneficial in 
attenuating tauopathies. Activating autophagy with rapamycin was recently shown to 
have efficacy in a transgenic model of tauopathy,27, 28 potentially ushering in a new 
avenue for tau expression reducing strategies aimed at autophagic pathways. For 
example, molecules enhancing autophagosome biogenesis and inhibiting the mammalian 
target of rapamycin (mTOR) both stimulate autophagic tau clearance.29 Thus, continuing 
to identify novel small molecules that regulate tau metabolism through these protein 
clearance pathways could allow us to better understand tau and proteostasis processes 
as well as serve as a foundation for drug discovery efforts to treat tauopathies. 
 
2.3 Results and Discussion  
  We previously showed that a scalemic isolate from myricanol (1) (86% ee (+)-
aR,11S-myricanol (2)) (Figure 2.1), a natural product derived from Myrica cerifera 
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(bayberry/southern wax myrtle) root bark, lowered tau levels,30 but the relevance of the 
stereochemistry and the mechanism through which this occurred remained unknown.31 
One of the obstacles has been to obtain high yields of 2, and its enantiomer 3, via 
synthetic means with completely characterized structure and purity.32-34 In addition to 
improving the isolation of 1 from M. cerifera root bark,30 we here devised a novel synthetic 
route for its production. The first reported synthesis of 1 relied upon the Ni(0)-mediated 
coupling of a bis-iodide intermediate, in ~10% yield.32  The synthesis of 1 employed the 
intramolecular cross coupling of an aryl boronic acid pinacol ester and an aryl iodide, as 
the boronic acid pinacol ester functionality has been established as a useful partner in 
macrocycle ring formation.35 Arylbromide 4 was converted to phenylpropionaldehyde 5 
by palladium-mediated reductive coupling with allyl alcohol (Figure 2.1).  Iodination of 5 
proceeded primarily ortho to the methoxy group to give 6, in 76% yield.  4-(4-
Benzyloxy)butan-2-one 7 was converted to iodide 8, which then afforded boronic acid 
pinacol ester 9.  Intermediate 9 was treated with LDA followed by 6 to effect an aldol 
condensation to give 10, after acid-mediated elimination to the α,β-unsaturated ketone, 
in 39% overall yield.  Intramolecular cyclization of 10 using a palladium catalyst gave 
desired 11 in 22% yield.  We also conducted experiments on related substrates bearing 
two iodines without the boron acid pinacol ester using Ni(0) catalysts, which had also 
been reported in the synthesis of the related natural product alnusone36 but found no 
improvement over the ~10% yield reported earlier.32  The olefin was reduced and the 
benzyl ethers of 11 were removed via hydrogenolysis, to give 12, reduction of which gave 
1 (Figure 2.1).  
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M. cerifera-derived 1 is a m,m-bridged diarylheptanoid consisting of the two 
enantiomers 2 and 3, but 2 is in enantiomeric excess (~13:1 ratio).30 It could also possess 
the two atropisomers, 2a and 3a (Figure 2.2A). To determine if synthetic 1 had a similar 
enantiomer composition as purified 1, it was subjected to chiral separation by high 
performance liquid chromatography (HPLC), resulting in two UV fraction peaks with 
identical retention times as those observed for M. cerifera-derived 1 but at a 1:1 ratio 
(Figure 2.2A and 2.2B). Crystal structures were obtained of the racemic purified 1 and the 
purified enantiomer 2, allowing us to infer the structure of 3 (Figure 2.2C and 2.2D).  
Analysis of the solid state structure shows the stereochemistry of the hydroxyl group on 
the macrocyclic ring appears to direct two opposite atropisomer geometries relative to the 
biphenyl rings, which are highly strained. The internal dihedral angle of the biphenyl is 
31.5o, relative to the carbocyclic ring, whereas the external dihedral angle is 45.1o, which 
means a 13.4o twist in the phenyl rings for the two rings combined.  There is a 7-
membered ring hydrogen bond between the 5-OH and 4-OMe groups on the biphenyl 
rings (2.6 Å between non-hydrogen atoms).37, 38   
Previously, we showed that scalemic 1 isolated from M. cerifera had anti-tau 
activity, while racemic 1 derived from another source did not.30 Therefore, we wanted to 
determine whether synthetic 1 had efficacy against tau similar to M. cerifera-derived 1. 
Indeed, using HEK293T cells stably overexpressing P301L tau (an FTD-causing mutation 
prone to aggregation; HEK P301L) we confirmed that this newly synthesized 1 did in fact 
lower tau levels (Figure B.1). Also in our previous work, we hypothesized that 2 was the 
more abundant chiral isolate from 1 because it was the enantiomer in excess in 1 derived 
from M. cerifera. However, this hypothesis was never confirmed because we did not 
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isolate the enantiomers and analyze their anti-tau efficacy individually. Above, we 
determined that both synthetic and M. cerifera-derived 1 only contained two of the four 
possible isomers of 1; 2 and 3. But M. cerifera-derived 1 had a 14:1 ratio of 2 to 3, while 
synthetic 1 had a 1:1 ratio (Figure 2.2). Therefore, we sought to determine if these 
enantiomers each had anti-tau activity, or whether one of these was driving the majority 
of the anti-tau efficacy of 1. HEK P301L cells were treated with either 2 or 3 over a 72 h 
timecourse. Surprisingly, 30 µM of 3 decreased both phosphorylated and total tau levels 
similarly after just 6 h treatment and levels were reduced by as much as 50% after 72 h. 
In contrast, treatment with 2 at 30 µM did not reduce tau levels throughout the duration of 
the experiment in this cell model (Figure 2.3A and 2.3B) despite previous work showing 
anti-tau activity at higher concentrations.30 These surprising results indicated that the 
chirality of 1 based on the asymmetric carbon C-11 of the macrocyclic ring and the 
biphenyl atropisomerism are indeed essential for the anti-tau activity of 1, but not as 
originally predicted based on the enantiomer excess inference.30 Instead, it is the minor 
constituent of 1, 3, that is responsible for the majority of tau-lowering activity. Therefore, 
any preparation of racemic 1 that possesses 2 and 3 together should have anti-tau 
activity, but not all preparations of racemic 1 may lower tau levels because they could 
possess a different isomer profile.  
Our previous interpretation was based on an inference of two racemic mixtures of 
naturally derived myricanol from two different sources; one from M. cerifera and the other 
from another source not disclosed by Indofine Chemical, but was likely from Myrica rubra, 
which is the typical source. The X-ray data from M. cerifera-derived myricanol that we 
prepared here revealed the presence of only 2 isomers. However, no X-ray data was 
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collected on the racemic material obtained from Indofine Chemical, which possibly 
possessed a distinct stereoisomer profile from our previous work.30 This could be due to 
environmental or species differences between where the material used here and the 
material used by Indofine Chemical were harvested and/or the methods used for 
extracting the natural product. Either modification could result in epimerization of the 
atropisomers. Also while in our previous work the chiral column HPLC revealed two peaks 
in the racemic mixture from Indofine Chemical that appeared similar to the mixture we 
isolated from M. cerifera ourselves, it is likely that the atropisomerism could not be 
resolved with the column that we used. Another consideration is that the myricanol 
purchased from Indofine Chemical may have lacked the same purity as the myricanol that 
we purified. Any of these alterations could possibly explain the lack of activity of the 55:45 
racemic preparation used in our previous work. Because of this unexpected result, we 
were also concerned that 3 was possibly being metabolized in the cell, particularly given 
its polyphenolic structure. Therefore we subjected lysates of cells treated with 3 for 1, 6, 
and 24 hours to liquid chromatography mass spectrometry (LC-MS) analysis. 
Interestingly, the amount of 3 found in cells increased over time likely due to cell 
permeability and more importantly, there was no metabolite observed (Figure B.2). This 
confirmed that 3 was indeed the active molecule.      
We then compared the anti-tau activity of 3 to another well-established tau-
reducing compound, YM-01.39 HEK P301L cells were treated with increasing 
concentrations of 3 and YM-01 for 24 h (Figure 2.3C). YM-01 reduced the levels of tau at 
lower concentrations than 3, but the difference was slight (IC50= 3 µM and 18 µM Figure 
2.3D). We examined whether 24 h 3 treatment reduced the levels of other known tau 
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mutations associated with disease. HEK293T cells were transfected with P301L, wildtype 
(WT), G303V, V337M, R406W tau species containing all four microtubule binding 
domains and no N-terminal insertions (4R0N) and were treated with the IC50 of either YM-
01 (3 µM) or 3 (18 µM) for 24 h. While tau levels in most of these mutants were reduced 
by either treatment, R406W tau was resistant to both compounds (Figure 2.3E and 2.3F). 
This corroborates previous work showing that this particular tau mutant (R406W) is more 
resistant to tau expression reducing agents, perhaps because of its more hydrophobic 
structure.15  
Next, we tested the anti-tau activity of 3 in a more physiologically relevant context, 
using brain tissue from the rTg4510 mouse model, which overexpresses P301L tau.40  
Acute ex-vivo brain slices were treated with YM-01 and 3 (Figure 2.3G) for 6 h.39, 41 These 
slices can only survive for approximately 6-8 h. Therefore higher concentrations of 
treatments are typically used to accelerate manifestation of activity. YM-01 significantly 
reduced tau levels at 30 and 100 µM, as previously described.39 (-)-aS,11R-myricanol (3) 
also significantly decreased tau levels in rTg4510 brain slices at higher concentrations 
(100 and 150 µM) (Figure 2.3H).  Thus, enantiomer 3 reduced tau levels in both cultured 
cells and an ex vivo model of tauopathy.  
We then sought to investigate the kinetics of tau clearance caused by 3 treatment. 
To do this, we used a previously characterized cell model, the inducible iHEK WT tau cell 
line.41 This cell model allows us to monitor the degradation of tau protein exclusively by 
turning tau expression on and then off using tetracycline and monitoring tau levels after 
transgene expression is suppressed. To assess how 3 affected tau degradation, iHEK 
cells were induced to overexpress tau for 24 h and then tau expression was shut off by 
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removal of the tetracycline. Cells were then treated with 3 over 24 h.  After 6 and 24 h, 3 
significantly enhanced the temporal clearance of tau protein compared to cells treated 
with vehicle only (Figure 2.4A and 4B). This tau-specific chase experiment confirmed that 
3 was in fact accelerating tau clearance, not regulating its production.   
Using this same model, we investigated how 3 was impacting other well-known tau 
epitopes. Tau expression was induced with tetracycline in iHEK WT tau cells for 24 h and 
then tetracycline was removed to stop tau expression. Cells were then treated with 3 and 
lysates harvested at indicated timepoints.  After 1 h, 3 accelerated reductions of tau 
phosphorylated at S396/S404 and T231 compared to cells treated with vehicle alone. 
Levels of tau phosphorylated at S262 and S356 were unchanged compared to vehicle 
treated cells, consistent with previous findings that this particular phospho-tau species is 
resistant to tau-lowering agents15, 18 (Figure 2.4C and 4D). The clearance of both total tau 
species (epitopes were αα 2-18, or 404-441) was accelerated by 3, but this occurred more 
slowly than it did for pS396/S404 and T231 tau species. Thus, select phospho-tau species 
are rapidly reduced by 3 treatment, while total tau levels are reduced, but with greater 
latency.  
We previously demonstrated that the anti-tau activity compound, YM-01, promoted 
tau clearance through an ubiquitin-dependent proteasomal mechanism.39 This is 
indicated by the accumulation of high molecular weight tau species following treatment 
with YM-01 in HEK P301L cells (Figure 2.5A). However, we observed that treating these 
same cells with 3 did not produce high molecular weight tau (Figure 2.5B). We also 
showed previously that YM-01-mediated tau expression reduction was blocked when 
cells were co-treated with a proteasomal inhibitor,39 but treating cells with the proteasomal 
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inhibitor MG-132 had no impact on the anti-tau activity of 3 (Figure 2.5C and 5D), 
suggesting that 3 was clearing tau through an alternative non-proteasomal mechanism.  
We then turned to an unbiased approach to identify a possible mechanism that 
was triggered by 3 to facilitate tau clearance. We used SILAC proteomic analysis on 
lysates of the neuronal cell line (M17) treated with or without 3 to help elucidate its 
possible mechanism of action. These experiments were performed in triplicate and data 
was analyzed using the ingenuity pathway analysis (IPA) software. Any peptides 
represented in only one of these triplicates were excluded from the analysis. To identify 
which other compound(s) 3 most closely represented we turned to the top upstream 
regulator prediction feature of the IPA software. Based on our SILAC proteomic results, 
this feature allowed us to predict those compounds or proteins that activated or inhibited 
similar pathways to those modulated by 3.  Interestingly, the pathways activated by 3 
treatment were the same as those activated by the compound sirolimus/rapamycin (Table 
B.3). Rapamycin is a known autophagy activator and has previously been implicated as 
a possible treatment for tauopathy.42, 43 Based on this insight, HEK P301L tau cells were 
co-treated with the autophagy inhibitor, 3-methyladenine (3-MA) and 3. In the absence of 
3-MA, 3 reduced tau levels as expected; however, when 3-MA was present, 3 activity 
against tau was abrogated (Figure 2.6A and 6B). Compound 3 also induced LC3β in the 
iHEK cell model (Figure 2.6C), a protein known to be elevated when autophagy is 
activated.44, 45 These findings provided further evidence that part of the tau expression 
reducing activity of 3 was due to activation of autophagy.  
While 3 most closely resembled activated rapamycin signaling, there were other 
pathways that were predicted to be somewhat impacted by 3 treatment, albeit to a lesser 
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extent. Some of these pathways could be contributing to the effects of 3 on tau biology. 
For example, 3 was shown to regulate a variety of translational proteins from the EIF2, 
EIF4/p70S6K, and mTOR pathways (Table B.4). While our data from Figure 2.4 suggests 
that impaired translation of tau is not a major contributor to the tau-lowering activity of 3, 
it could be having some effect. In fact, we have previously shown that tau itself can alter 
the EIF2 pathway,46 further suggesting a link between this mechanism and tau. We also 
noticed that discreet phospho-tau species were being rapidly reduced by 3 (Figure 2.4C). 
The pS396/S404 and pT231 epitopes most affected by 3 (Figure 2.4C) were those 
typically phosphorylated by known serine/threonine tau kinases such as glycogen 
synthase kinase 3β (GSK3β), Casein kinase 2 (CK2) and mitogen activated protein 
kinase 1 (MAPK1/ERK2), as well as members of the protein kinase A family. While the 
levels of GSK3β itself were not directly influenced by 3 according to the proteomic data, 
an upstream kinase capable of modifying GSK3β signaling was; MAPK1/ERK247 (Table 
B.5). In addition, both CK2 and a member of the PKA family were also reduced by 3 
treatment (Table B.6). This could represent another mechanism through which 3 is 
regulating tau biology; by decreasing levels of tau kinases. Overall, while our data 
suggests that activation of autophagy is the major activity of 3 that promotes tau 
clearance, our proteomic data provides additional details about other mechanisms 
through which 3 could modify tau biology. 
 We then heated 1 in the presence of pTsOH for 24 h to try to eliminate the active 
stereocenters and reduce the OH group at C11.  The major product was the cyclized 
tetralin derivative 13, in 45% yield (Figure 2.7A).  We were surprised by the observation 
of this derivative because rather than having the expected m,m-bridged substitution 
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(compound 14) pattern the molecule had rearranged to an o,m-bridge as determined by 
X-ray crystallography (Figure 2.7B), likely because of the relief of ring strain in 1. The X-
ray crystal analysis of B showed the enantiomers of 13 as aR,10R and aS,10S but after 
chiral HPLC no assignment was determined for (+)-13 and (-)-13. Myricanone (12) has 
been reported to rearrange to 15 upon treatment with lewis acid boron trifluroride (BF3),48 
so we repeated this reaction.  Reduction of 15 using sodium borohydride gave 16, which 
is reported for the first time (Figure 2.7A). Interestingly, while compounds 12, 15, and 16 
were inactive against tau (not shown), compound 13 maintained anti-tau activity that was 
similar to 3, despite the rearrangement, alteration of the macrocycle ring and reduction of 
the hydroxyl group at C11 (Figure 2.8A and 8B). This was important because it suggested 
that the exposed hydroxyl moieties on the biphenyl motif were not causing tau 
degradation through a pan-assay interference phenomenon.49 The enantiomers of 13 
were separated and collected individually by chiral HPLC to evaluate whether the 
chiralities (C10 and 1, 19-biphenyl) of 13 were as important for activity as those (C11, 
1,2-biphenyl) for 3 were. Both (+)-13 ([α]20D = +93.6 (c= 0.08, chloroform)) and (-)-13 
([α]20D = -100 (c= 0.09, chloroform) had similar activity against tau (Figure 2.8C), 
suggesting that this molecule maintains anti-tau activity independent of chirality.  
In conclusion, we have developed a new synthetic route for the production of 1. 
The enantiomer 3 reduced tau levels in several models of tauopathy. This molecule 
promoted tau clearance by activating autophagy, but SILAC proteomic analysis 
suggested that other pathways may also be engaged to alter tau production and 
phosphorylation. We also produced 13, a derivative of 1, and both (+) and (-) enantiomers 
of 13 maintained tau expression reducing efficacy. We attributed this to several unique 
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structural features that emerged during the preparation of 13. This work represents a 
major step forward in understanding the stereochemistry and biochemistry of this scaffold, 
and perhaps defines 3 and 13 as early stage anti-tau therapeutics and tools for 
investigating autophagy. 
 
 
 
Figure 2.1. Synthesis of 1. 
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Figure 2.2. (continued on next page) Enantiomers of 1. a) Chemical structure of 1 
comprised of the two enantiomers 2 and 3, and possible atropisomers, 2a and 3a. b) 
Chiral HPLC traces of M. cerifera-derived myricanol, synthetic myricanol and M. cerifera-
derived myricanol/ synthetic myricanol (1:1) reveal 86%, 2% and 42% ee, respectively. c) 
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The single molecule of 2 shown is a part of a large asymmetric unit containing four 
molecules of 2; d) the structure represented as a co-crystal consisted of two enantiomers 
2 and 3 related by inversion center; Thermal displacement ellipsoids are drawn at 50% 
probability level. Coloring scheme – red (O), gray (C) and white (H). 
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Figure 2.3. (continued on next page) (-)-aS,11R-myricanol  (3) is the enantiomer 
responsible for anti-tau activity.  a) Representative western blot of lysates from 
HEK293T cells stably overexpressing P301L tau (HEK P301L tau) treated with 2 or 3 for 
indicated time points. b), Quantification of pTau (S396/404) and total tau (H150) levels 
from cells treated with indicated compound and harvested at indicated timepoints over 72 
h. c) Representative western blot of HEK P301L cells treated with indicated 
concentrations of each compound for 24 h.  d) Half maximal inhibitory values (IC50) were 
approximately 1.8 µM for YM-01 and 18.56 µM for 3. e) HEK293T cells were transiently 
transfected with disease causing tau mutants and treated with IC50 of each compound for 
24 h.  f) Schematic showing location of each mutation in the tau protein. g) Representative 
western blot of lysates from acute brain slices from 4 month old rTg4510 transgenic mice 
treated with indicated concentrations of YM-01 or 3 for 6 h.  h) Quantification of tau levels 
from g). Data are average ± standard error of the mean (SEM), n=3. Anti-tau activity of (-
)-aS,11R-myricanol  was observed in >10 individual experiments. 
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Figure 2.4. (-)-aS,11R-myricanol (3) significantly accelerates tau clearance and 
selectively reduces distinct tau species. a) Representative western blot of tau levels 
in tet-inducible HEK293 cells stably overexpressing WT 4R0N Tau (iHEK) treated with 3 
(18 µM) for indicated timepoints and harvested 24 h post tetracycline removal. b) 
Quantification of tau levels from a). Data are average ± standard error of the mean (SEM), 
n=3.  c) Representative western blot of tau levels in iHEK cells. Expression of WT Tau 
was induced for 24 h with tetracycline (1 mg mL-1). Tetracycline was removed and cells 
were all treated with 3 at the same time. Lysates were harvested at indicated timepoints 
and analyzed by western blot for levels of indicated tau species.  d) Quantification of 
levels of each tau species in panel c). Data are average ± SEM, n=3. 
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Figure 2.5. (-)-aS,11R-myricanol (3) clears tau through a non-proteasomal pathway. 
Representative western blot analysis of HEK293 cells transiently transfected P301L tau 
and treated with either YM-01 a) or 3 b) at indicated concentrations for 24 h.  c) 
Representative western blot of lysates from HEK P301L tau cells co-treated with 3 and 
proteosomal inhibitor, MG-132 for 4 h, harvested. d) Quantification of tau levels in panel 
c) as a percentage of vehicle treated ± standard error of the mean (SEM), n=3. 
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Figure 2.6. (-)-aS,11R-myricanol  (3) clears tau via autophagy. a) Representative 
western βlot of lysates from HEK P301L tau cells co-treated with 3 and the autophagy 
inhibitor, 3-methyladenine (3-MA), at indicated concentrations for 6 h. b) Quantification of 
tau levels in panel a) as a percentage of vehicle treated ± standard error of the mean 
(SEM), n=3. c) Representative western blot of LC3β levels in iHEK cells. Expression of 
WT Tau was induced for 24 h with tetracycline (1 mg mL-1). Tetracycline was removed 
and cells were all treated with 3 at the same time. Lysates were harvested at indicated 
timepoints and analyzed by western blot for levels of LC3β. Densitometric values are 
average ± SEM. 
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Figure 2.7.  Synthesis of 16, and a cyclized tetralin derivative thereof, 13.  a) The 
acid mediated dehydration of 1 produced cyclized tetralin 13 as the major product, in 
which a rearrangement occurred. Compound 15 was prepared as described and reduced 
to 16. b) The structure of 13 represented as a co-crystal consisted of two enantiomers 
related by inversion center. Thermal displacement ellipsoids are drawn at 50% propability 
level. Coloring scheme – red (O), gray (C) and white (H). 
B
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Figure 2.8. Tau levels are decreased by 16-like tetralin derivative 13. a) 
Representative western blot analysis of HeLa cells stably expressing 4R0N tau and 
treated with compound 13 at indicated concentrations for 24 h. b) Representative western 
blot analysis of HeLa tau cells and treated with compound 13 at 50 µM for indicated 
timepoints.  c) Representative western blot analysis of HeLa tau cells treated with either 
(+)-13 or (-)-13 at indicated concentrations for 24 h. 
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2.4 Materials and Methods  
2.4.1 Methods 
  All chemicals and anhydrous solvents were purchased from commercially 
available sources and used without additional purification. General solvents and reagents 
were purchased from Fisher Scientific. HRMS was performed on JMS-T100LC AccuTOF 
Reflectron Time-of-Flight Mass Spectrometer with ESI source, MS-50010BU TOFMS 
Base unit; Resolution: 6,000 (FWHM), 5 ppm accuracy of mass value; and Agilent 7980 
Gas Chromatography Quadrupole time of Flight Mass Spectrometer 7200 series with EI 
source. 1H NMR spectra were obtained on a Varian Mercury 300-MHz NMR and Varian 
500-MHz NMR DD cryoprobe. Chemical shifts are reported in parts per million (ppm, δ) 
using various solvents as internal standards (CDCl3, δ 7.26; DMSO-d6, δ 2.50). 1H-NMR 
splitting patterns were designated as singlet (s), doublet (d), triplet (t), or quartet (q). 
Splitting patterns that could not be interpreted or easily visualized are recorded as 
multiplet (m) or broad (br). Coupling constants were reported in hertz (Hz).  Purity (%) 
and mass spectral data were determined with a Waters Alliance 2695 HPLC/MS (Waters 
Symmetry C18, 4.6 x 75 mm, 3.5 µm) equipped with a 2996 diode array detector from 
210–400 nm; the solvent system is 5-95% acetonitrile in water with 0.1% TFA over 9 min 
using a linear gradient. The chiral separation was performed with a Shimadzu 10AT HPLC 
(Phenomenex Lux Cellulose-1, 10 x 250 mm, 5 µm) equipped with a SPD-10Av detector 
at 254 nm; isocratic solvent system 1 of 5% isopropanol in hexane and isocratic solvent 
system 2 of 3% isopropanol in hexane at a flow rate of 5 mL min-1 and retention times are 
in minutes. 
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2.4.2 Reagents 
YM-01 was provided by J. Gestwicki. MG-132 was obtained from AG Scientific and 
3-MA was obtained from Sigma Aldrich. 3-MA was solubilized in water to 0.2 M. All other 
compounds were all solubilized in DMSO (Sigma Aldrich) to 30 mM. Lipofectamine 2000 
from Invitrogen was used for all transfections. 
 
2.4.3 Cell Culture  
HEK293T (ATCC) cells stably expressing P301L 4R0N tau, BE(2)-M17 (ATCC) 
cells and HEK293T cells were maintained in DMEM plus 10% FBS (Life Technologies), 
1% Penicilin Streptomycin (Invitrogen), and 1% Glutamax (complete media; Thermo 
Scientific). HEK293T cells stably overexpressing tetracycline regulatable WT Tau 4R0N 
cells were maintained under Zeocin and Blasticidin S HCl (Invitrogen) selection in 
complete DMEM. HeLa (ATCC) cells stably expressing V5-tagged 4R0N tau15 were 
maintained under G418 selection in Opti-Mem plus 10% FBS (complete media; 
Invitrogen) as previously described.15 Transfections were performed following Invitrogen 
Plasmid DNA Transfection protocol using Opti-MEM.  All cells were treated as indicated 
and were harvested as previously described.15 Cells were washed twice in ice-cold PBS 
then scraped in cold MPER (Fisher Scientific) containing protease and phosphatase 
inhibitors (PIC III, Calbiochem, PI2 and PI3, Sigma, PMSF).  Samples were allowed to 
incubate on ice, vortexed, then centrifuged at 10,000 rpm for 5 min at 4°C to clear debris.  
 
2.4.4 Ex Vivo Slice Cultures 
All procedures involving experimentation on animal subjects were done in accord 
with the guidelines set forth by the Institutional Animal Care and Use Committee of the 
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University of South Florida.  Male 4 month old rTG4510 slice cultures were treated and 
maintained as previously described.30   
 
2.4.5 Western blotting  
After normalization of protein concentration by bicinchoninic acid (BCA) 
(ThermoFisher), samples were run on 10% SDS-PAGE gels, transferred to PVDF 
(Immobilon, EMD Millipore).  Membranes were blocked for 1h in 7% nonfat dry milk in 
TBS-T before probing with anti-tau antibodies H150 (Santa Cruz Biotechnology), and 
pT231 (Anaspec). Anti-actin and anti-GAPDH were purchased from Sigma Aldrich and 
Biodesign. All antibodies were used at a dilution of 1:1,000. Anti-S396/S404 
phosphorylated tau antibody (pS396/404) was used at a dilution of 1:500 (provided by P. 
Davies). Primary antibodies were decteced by the species appropriate secondary 
antibodies (Southern Biotech).  Antibodies were detected by ECL (ThermoFisher).  
 
2.4.6 Densitometry (Quant) 
All values are shown as percent vehicle following actin normalization ± standard 
error and mean. Scion Image software was used to calculate densitometry of all western 
blots. 
 
2.4.7 SILAC/Proteomic analysis  
M17 neuroblastoma cells were labeled for quantitation using SILAC media 
supplemented with 10% dialyzed FBS, pen/strep, and L-lysine or 13C6-L-Lysine 2HCl for 
M17 neuroblastoma cells (Thermo Scientific). Cells were maintained in T25 flasks and 
subsequent procedure was followed as described in M17 neuroblastoma cells were 
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labeled for quantitation using SILAC media supplemented with 10% dialyzed FBS, 
pen/strep, and L-lysine or 13C6-L-Lysine 2HCl for M17 neuroblastoma cells (Thermo 
Scientific). Cells were maintained in T25 flasks and subsequent procedure was followed 
as previously described.50 SILAC-fed neuronal M17 cells were treated with 3 or vehicle 
for 72 h. Quantification was done using the Ingenuity Pathway Analysis software. The 
experiment was performed in triplicate. Proteins without peptide representation in at least 
two of the triplicates were excluded from the analysis.  
 
2.4.8 Statistics   
Statistical analyses were performed by one-way ANOVA tests or Student’s t-tests. 
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CHAPTER THREE: 
 
INHIBITION OF BOTH HSP70 ACTIVITY AND TAU AGGREGATION IN VITRO BEST 
PREDICTS TAU LOWERING ACTIVITY OF SMALL MOLECULES 
“Reproduced (or 'Reproduced in part') with permission from [Martin, M. D., Baker, J. D., Suntharalingam, 
A., Nordhues, B. A., Shelton, L. B., Zheng, D., Sabbagh, J. J., Haystead, T. A., Gestwicki, J. E., and Dickey, 
C. A. (2016) Inhibition of Both Hsp70 Activity and Tau Aggregation In Vitro Best Predicts Tau Lowering 
Activity of Small Molecules, ACS Chem Biol.] Copyright [2016] American Chemical Society." 
 
3.1 Abstract 
The phenothiazine, rhodacyanine, and flavonol scaffolds with inhibitory activity 
against the heat shock protein 70 (Hsp70) family of chaperones have been found to 
enhance the degradation of the microtubule associated protein tau in cells, neurons and 
brain tissue. This is important because tau accumulation is linked to neurodegenerative 
diseases including Alzheimer’s disease (AD) and chronic traumatic encephalopathy 
(CTE). Here we expanded upon this study to investigate the anti-tau efficacy of additional 
scaffolds with Hsp70 inhibitory activity. Five of the nine scaffolds tested lowered tau 
levels, with the rhodacyanine and phenothiazine scaffolds exhibiting the highest potency 
as previously described. Because phenothiazines also inhibit tau aggregation in vitro, we 
suspected that this activity might be a more accurate predictor of anti-tau activity. 
Interestingly, the rhodacyanines did inhibit in vitro tau aggregation to a similar degree as 
phenothiazines, correlating well with tau expression reducing efficacy in cells and ex vivo 
slices. Moreover, other Hsp70 inhibitor scaffolds with weaker tau expression reducing 
activity in cells inhibited tau aggregation in vitro, albeit at lower potencies. When we tested 
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six well-characterized tau aggregation inhibitors, we determined that this mechanism of 
action was not a better predictor of tau expression reduction than Hsp70 inhibition. 
Instead we found that compounds possessing both activities were the most effective at 
promoting tau clearance. Moreover, cytotoxicity and PAINS activity are critical factors that 
can lead to false-positive lead identification. Strategies designed around these principles 
will likely yield more efficacious tau expression reducing compounds. 
 
3.2 Introduction 
Aggregation and accumulation of the microtubule associated protein tau is a 
common feature of several neurodegenerative diseases, referred to as tauopathies, 
which include chronic traumatic encephalopathy (CTE), Alzheimer’s disease (AD), frontal 
temporal dementia linked to chromosome 17 (FTDP-17), Parkinson’s disease and Pick’s 
disease.1, 2 A plethora of therapeutic strategies have been employed to attempt to prevent 
aberrant tau accumulation and toxicity, including kinase inhibitors, humanized antibodies, 
aggregation inhibitors, microtubule stabilizing compounds and small molecules targeting 
degradation machinery.3-11 Some of our original work sought to identify molecules that 
could simply facilitate tau clearance, regardless of any particular known mechanism of 
action. 12, 13  While many of the compounds identified were largely cytotoxic, leading to a 
perceived reduction in tau, through these studies, we were able to identify chaperone 
modulators as one family of compounds capable of anti-tau activity independent of this 
toxicity.12 In particular, inhibitors of the Hsp70 chaperone family are highly effective at 
lowering tau.8, 14 When the activity of these molecular chaperones is pharmacologically 
or even genetically inhibited, tau can be degraded.15-18 Recently a number of other small 
molecules with anti-Hsp70 activity have been described. Some of these Hsp70 inhibitor 
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scaffolds mimic ATP and act as a competitive inhibitor in the ATP pocket, while others 
are thought to act allosterically, blocking cofactor or substrate interactions.19, 20, 8, 9, 21-25, 
26, 27, 28 But, the activity of these compounds against tau remains unknown. 
In addition, several of the published molecules with Hsp70 inhibitory activity are 
known to have other mechanisms of action, perhaps as a result of their prevalence in 
existing chemical libraries and their possible pan-assay interference properties. In 
particular, the phenothiazine, methylene blue (MB), which has been identified as a potent 
Hsp70 inhibitor and an autophagy inducer, also possesses other activities due to its redox 
potential. 22, 45 In fact, one such activity is inhibition of tau aggregation in vitro, an activity 
that was discovered two decades ago.34 MB is thought to inhibit tau aggregation by 
covalent modification of tau via cysteine oxidation.29, 30 Because tau has two naturally 
occurring cysteine residues located in the microtubule binding domain, it can form 
intermolecular disulfide bonds with neighboring tau molecules leading to aggregate 
formation.31-33 MB creates disulfide bonds within the same tau molecule disrupting 
fibrillization.29 Since MB has been shown to reduce tau levels in multiple tauopathy 
models34-36 , which has precipitated clinical trials of related derivatives for AD and FTD, it 
is difficult to know which activity, Hsp70 inhibition or aggregation inhibition, is most 
responsible for its ability to facilitate tau clearance.34, 37, 38 In this regard, several other 
studies have identified tau aggregation inhibitors, but the ability of these compounds to 
promote tau clearance has not been presented for most of these. For example, the olive 
oil phenols, aminothienopyridazine (ATPZ), rhodanines and anthraquinones all prevent 
tau aggregation in vitro, yet it is not known if this activity is sufficient to facilitate tau 
reductions in living cells. 39 6, 40-42  
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Based on this information, we sought to evaluate if Hsp70 or aggregation inhibition 
was a better predictor of tau expression reduction in cells. With this in mind, we collected 
a number of known Hsp70 and aggregation inhibitors, and assessed their activities 
against tau. Interestingly, neither in vitro activity alone was a strong predictor of anti-tau 
activity in cells. Rather, only those molecules possessing potent activity against both 
Hsp70 ATPase function and tau aggregation in vitro, facilitated tau clearance independent 
of toxicity. Here, we describe the implications of these findings for tau-based drug 
discovery efforts, and how this information could be used to improve the success rate for 
translation of leads identified from in vitro assays into pre-clinical and clinical studies. 
 
3.3 Results and Discussion 
Based on our previous reports that methylene blue and the compound YM-01, a 
derivative of MKT-077 from the rhodacyanine scaffold, both inhibited Hsp70 activity and 
lowered tau levels in a cell tauopathy model8, 14, we hypothesized that it was in fact the 
Hsp70 ATPase inhibition that was the best predictor of anti-tau activity in cells. To 
investigate this, we examined the tau expression reducing capability of several other 
published Hsp70 inhibitors, listed in Table 3.1.  Compounds for each scaffold were 
assessed for tau-lowering efficacy. Human embryonic kidney (HEK293T) cells, transiently 
overexpressing WT4R0N tau were treated with increasing concentrations of each 
compound for 24 h. Interestingly, vast differences in tau-lowering activity were found 
among the molecules. Compounds from the piperidine-3-carboxamide and the adenosine 
analog scaffolds surprisingly increased tau levels. In contrast, the rhodacyanine and 
phenothiazine compounds still potently reduced tau levels at all concentrations. However 
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the dihydropyrimidine, phenoxy-N-arylacetamide, sulfonamide, and flavonol scaffolds 
only lowered tau levels at the highest concentration tested, 30 µM (Figure 3.1A,B). Similar 
trends were observed for these compounds in a stably transfected HEK P301L tau cell 
line (Figure C.1). These data indicate that allosteric Hsp70 inhibitors might be more likely 
to possess tau-lowering activity than those that directly target the ATP binding site. 
Perhaps more importantly, because all of these compounds target the same mechanism 
of action, we concluded that Hsp70 inhibition alone was insufficient to predict anti-tau 
activity by greater than ~60% predictive accuracy. 
Because methylene blue also inhibits in vitro tau aggregation, we then speculated 
that tau expression reducing efficacy could be better predicted by in vitro anti-tau 
aggregation activity. To test this, we evaluated the anti-tau activity of several 
commercially available tau aggregation inhibitor scaffolds including carbocyanine, 
aminothienopyridazine (ATPZ), polyphenols, anthraquinone, and rhodanine (Table 3.2). 
Surprisingly, only two of these compounds lowered tau levels in our HEK293T tauopathy 
cell model; carbocyanine and anthraquinone (Figure 3.2A,B). However, the activity of 
carbocyanine coincided with very high cytotoxicity as suggested by the reduced actin 
levels. Thus, only the anthraquinone at 30µM effectively lowered tau levels, possibly 
suggesting another unknown mechanism for this particular molecule. In this way, tau 
aggregation inhibition alone is an even worse predictor of anti-tau activity than Hsp70 
inhibition.  
Since neither of these mechanisms alone was sufficient to predict anti-tau activity, 
we speculated that perhaps compounds with dual activities might be more likely to 
facilitate tau clearance in cells. This was largely based on the known pleiotropy of 
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methylene blue. Therefore, we investigated whether those Hsp70 inhibitors capable of 
lowering tau might also have activity against its aggregation in vitro. To test this, 10 µM 
4R0N human recombinant tau was incubated with each compound at increasing 
concentrations for 1 h at 37°C. After one hour incubation, 10 µM heparin was added to 
the tau compound mixture and incubated for a further 24 h at 37°C prior to reading the 
fluorescent intensity of each mixture. Increases in fluorescence intensity indicate 
enhanced tau amyloid formation. Interestingly, we found that compounds from the 
rhodacyanine and phenothiazine scaffolds had high anti-tau aggregation potency with 
IC50s of .813 µM and 1.35 µM, respectively. Less potent tau-lowering scaffolds such as 
dihydropyrimidine, phenoxy-N-arylacetamide, and flavonols had higher IC50s (22.7, 6.93, 
and 9.74 µM, respectively). In contrast the compounds that increased tau levels in our 
cell model, piperidine-3-carboxamide and adenosine analog, also increased tau 
aggregation levels in vitro (Figure 3.3A). To confirm in vitro anti-tau aggregation activity 
of the tau-lowering compounds, non-denaturing gel electrophoresis was performed. The 
most potent tau-lowering scaffold compounds, rhodacyanine and phenothiazine, also 
most potently reduced high molecular weight tau compared to other compounds and the 
tau alone control; however all compounds with anti-tau activity also reduced high 
molecular weight tau aggregation (Figure 3.3B,C). Since MB is known to alter cysteine 
oxidation in tau, a mechanism that can contribute to its anti-aggregation activity, 29 we 
suspected that the rhodacyanines may be acting through a similar mechanism. However, 
when we tested for the production of hydrogen peroxide following incubation of 
recombinant tau with 30 µM rhodacyanine, no significant differences were observed 
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(Figure C.2). Thus, those compounds capable of inhibiting both Hsp70 activity and tau 
aggregation in vitro predicted tau lowering activity by ~80% predictive accuracy. 
One interesting outcome from these analyses was the discovery that the anti-
aggregant compound ATPZ did not lead to tau expression reduction, despite it having the 
same exact anti-aggregation mechanism as MB; alteration of cysteine oxidation.29 We 
speculated that the lack of tau-lowering activity may be due to ATPZ’s inability to inhibit 
Hsp70 ATPase activity. Therefore we examined the Hsp70 inhibitory activity of not only 
ATPZ but of each aggregation inhibitor. Recombinant human Hsp70 and DnaJA2 were 
incubated with increasing concentrations of each compound for 30 min, followed by 
addition of ATP and subsequent 3 h incubation. We measured absorbance by malachite 
green assay as previously described21. None of the aggregation inhibitor scaffolds that 
failed to lowered tau inhibited Hsp70 ATPase activity, with the exception of the rhodanine 
scaffold (Figure 3.4), a known PAINS molecule that can be effective in any assay due to 
Michael reactions.43, 44   
One final variable that we needed to consider for these results was the role of 
cytotoxicity in perceived tau reductions. We previously found that compounds with high 
cytotoxicity caused tau expression reduction, perhaps due to microtubule breakdown.12, 
45, 46 We speculated this to be the case for the carbocyanine and possibly some of the 
other outliers in these studies. Therefore, we tested the cytotoxicity of all compounds at 
increasing concentrations using a lactate dehydrogenase (LDH) assay. The data revealed 
that the both the sulfonamide compound and the carbocyanine had high toxicity relative 
to the other compounds, explaining why they were leading to perceived tau reductions 
(Figure 3.5). Thus, compounds with activity against both Hsp70 activity and tau 
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aggregation in vitro can predict anti-tau activity at greater than 90% predictive accuracy 
when both cytotoxicity and PAINS classification are accounted for. 
 Overall neither Hsp70 inhibition nor anti-tau aggregation activity alone is sufficient 
to predict tau lowering in an in vitro model by more than 50%, although Hsp70 inhibition 
appears to be a better predictor than aggregation inhibition. But compounds that possess 
both activities, exemplified by the phenothiazines and rhodacyanines, are highly likely to 
promote tau clearance in cells and neurons (Figure C.3). Importantly, the higher the 
potency of Hsp70 inhibitors against tau aggregation, the more potent the tau-lowering, 
suggesting a synergy of these two mechanisms. Perhaps compounds with both activities 
can keep tau in a unique conformation that better facilitates its clearance. While there are 
certainly other mechanisms of tau clearance and molecules with distinct activities that 
could lead to tau degradation, these findings suggest that a drug screening campaign 
based first on Hsp70 inhibition with follow up assays examining tau aggregation, 
cytotoxicity and pan-assay interference, will likely yield less false-positive leads with 
regard to cellular activity against tau.47 This concept of polypharmacy has been gaining 
ground over the past few years. While target specificity is still a major goal of modern 
drug discovery, it is clear that compounds with multiple targets can have clinical benefit 
despite their pleiotropy.48-50 In particular, compounds that target multiple relevant 
mechanisms for single diseases may be more effective than compounds with single 
mechanisms of action.48, 49 
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Table 3.1. Summary of published Hsp70 inhibitors. 
Scaffold  Nomenclature  
(Compound Name) 
 
Compound Structure Hsp70/Dna
J 
Inhibitory 
Activity 
Reported 
Hsp70 
Family 
member 
targeted 
Anti-Tau 
Activity 
Reported 
Rhodacyanine 3-benzyl-2-((Z)-((E)-5-(6-chloro-3-
methylbenzo[d]thiazol-2(3H)-
ylidene)-3-ethyl-4-oxothiazolidin-2-
ylidene)methyl)thiazol-3-ium 
chloride 
(JG-98) 
Cl S
N
N
S
O
N
S
 
(Li et al., 
2013; 
Rousaki et 
al., 2011) 
HSPA8 
(Hsc70); 
HSPA9 
(Mortalin
);  
HSPA1 
(Hsp72); 
SSA1 
(Hsp70 
yeast) 
DnaK 
(Hsp70 
Bacterial
) 
(Fontaine 
et al., 
2015; 
Rousaki 
et al., 
2011) 
Dihydropyrimidi
ne 
4-[1,1′-Biphenyl]-4-yl-3,4-dihydro-
6-methyl-2-oxo-5-
[(phenylmethoxy)carbonyl]-1(2H)-
pyrimidinehexanoic acid 
(116-9E) 
H
N
N
O
HO
O
O
O
 
(Chang et 
al., 2008; 
Wisen et 
al., 2010) 
DnaK 
(Hsp70 
Bacterial
) 
Unknown 
Phenothiazine 3,7-
bis(Dimethylamino)phenazathioniu
m chloride 
(Methylene Blue) 
NS+
N
N
Cl
 
(Chang et 
al., 2008; 
Jinwal et 
al., 2009; 
Miyata et 
al., 2012) 
HSPA1 
(Hsp72) 
(Jinwal et 
al., 2009; 
Wischik, 
Edwards, 
Lai, Roth, 
& 
Harringto
n, 1996) 
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Table 3.1 (Continued) 
Piperidine-3-
Carboxamide 
(S)-N-(1-propyl-1H-benzimidazol-
2-yl)-1-(2-pyrazinyl)piperidine-3-
carboxamide 
(HS72) 
N
N
N
H
O
N
N
N
 
(Howe et 
al., 2014) 
HSPA1 
(Hsp72) 
Unknown 
Adenosine 
Analog 
5′-O-[(4-Cyanophenyl)methyl]-8-
[[(3,4-
dichlorophenyl)methyl]amino]-
adenosine  
(VER-155008) 
O
HO
OH
O
N
N
N
N
N
H2N
HN
Cl
Cl
 
(Williamson 
et al., 2009) 
HSPA8 
(Hsc70);  
HSPA1 
(Hsp72) 
 
Unknown 
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Table 3.1 (Continued) 
Phenoxy-N-
Arylacetamide 
butyl 3-[2-(2,4-
dichlorophenoxy)acetamido]benzo
ate 
(ALSB-2970) 
OO
N
H
O
O
Cl
 
(Cassel, 
Ilyin, 
McDonnell, 
& Reitz, 
2012) 
targets 
and 
binds to 
DNAJ 
Unknown 
Sulfonamide 2-Phenylethynesulfonamide 
(PES) 
 S
O
O
NH2
 
(Leu, 
Pimkina, 
Frank, 
Murphy, & 
George, 
2009) 
HSPA1 
(Hsp72) 
DnaK 
(Hsp70 
Bacterial
) 
Unknown 
Flavonol 3,3′,4′,5,5′,7-Hexahydroxyflavone 
(Myricetin) 
O
OH
O
OH
HO
OH
OH
OH
 
(Chang et 
al., 2008; 
Chang et 
al., 2011; 
Jinwal et 
al., 2009) 
HSPA8 
(Hsc70)  
DnaK 
(Hsp70 
Bacterial
) 
(Jinwal et 
al., 2009) 
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Figure 3.1. Diverse Hsp70 inhibitor scaffolds have differing effects on tau levels. 
(A) Representative western blot analysis of HEK293T cells transiently transfected 
WT4R0N tau and treated with each Hsp70 inhibitor at indicated concentrations for 24 h. 
(B) Quantification of tau levels in panel (A) as a percentage of vehicle treated ± standard 
error of the mean (SEM), n=3. By linear regression analyses, *** indicates p<0.001, ** 
indicates p<0.01. 
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Table 3.2. Summary of published tau aggregation inhibitor scaffolds. 
Scaffold  Nomenclature 
(Compound Name) 
Compound Structure Anti-Tau 
Aggregatio
n Inhibitory 
Activity 
Reported 
Tau 
Mutant 
Targete
d 
Intracellula
r Anti-Tau 
Activity 
Reported 
Carbocyanine 3,3′-Diethyl-9-
methylthiacarbocyanine 
iodide 
(C11) 
 
(Congdon et 
al., 2009; 
Duff, Kuret, 
& Congdon, 
2010) 
Wild 
Type 
(Congdon 
et al., 2009) 
Aminothienopyridazi
ne 
5-amino-3-(4-
chlorophenyl)-N-
cyclopropyl-4-oxo-3,4-
dihydrothieno[3,4-
d]pyridazine-1-
carboxamide 
(ATPZ) 
 
(Ballatore et 
al., 2010; 
Crowe et 
al., 2009) 
Wild 
Type; 
P301L; 
K311D 
Unknown 
Polyphenol (2S,3E,4S)-3-Ethylidene-
2-(β-D-
glucopyranosyloxy)-3,4-
dihydro-5-
(methoxycarbonyl)-2H-
pyran-4-acetic acid 2-
(3,4-
dihydroxyphenyl)ethyl 
ester 
(Oleuropein)  
(Daccache 
et al., 2011) 
P301L Unknown 
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Table 3.2 (Continued) 
Polyphenol 2-(3,4-
Dihydroxyphenyl)ethanol, 
3,4-Dihydroxyphenethyl 
alcohol 
(Hydroxytyrosol) 
 
(Daccache 
et al., 2011) 
P301L Unknown 
Anthraquinone 1,2,5,8-Tetrahydroxy-
9,10-anthraquinone, 
1,2,5,8-
Tetrahydroxyanthraquino
ne 
(Quinalizarin) 
 
(Duff et al., 
2010; 
Pickhardt et 
al., 2005) 
Wild 
Type; 
ΔK280 
Unknown 
Rhodanine 2-((Z)-5-((5-(3-
chlorophenyl)furan 
-2-yl)methylene)-4-oxo-2-
thioxothiazolidin-3- 
yl)ethanoic acid 
(Compound 1)  
(Bulic et al., 
2007; Bulic, 
Pickhardt, 
Mandelkow, 
& 
Mandelkow, 
2010) 
Wild 
Type; 
ΔK280 
Unknown 
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Figure 3.2. Diverse tau aggregation inhibitor scaffolds have differing effects on tau 
levels. (A) Representative western blot analysis of HEK293T cells transiently transfected 
WT4R0N tau and treated with each tau aggregation inhibitor at indicated concentrations 
for 24 h. (B) Quantification of tau levels in panel (A) as a percentage of vehicle treated ± 
standard error of the mean (SEM), n=3. By linear regression analyses, *** indicates 
p<0.001, ** indicates p<0.01, * indicates p<.05. 
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Figure 3.3. Diverse Hsp70 inhibitor scaffolds have differing effects on tau 
aggregation in vitro. (A) anti-Hsp70 compounds; quantification of in vitro ThT assay 
using recombinant P301L tau incubated with drug at increasing concentrations for one 
hour prior to addition of 20 µM heparin which was then incubated for 24 h. Data are 
average ± standard error of the mean (SEM), n=3. (B) Non-denaturing gel electrophoresis 
of anti-aggregation ThT samples from (A). (C) Quantification of tau aggregate levels from 
(B). Data are average ± standard error of the mean (SEM), n=3. 
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Figure 3.4. Tau aggregation inhibitor scaffolds do not inhibit Hsp70 ATPase 
activity.  Hsp70 Quantification of ATPase activity using recombinant human Hsp70 and 
DnaJA2 protein. Activities are a percentage of vehicle treated ± standard error of the 
mean (SEM), n=3. 
-2 -1 0 1 2 3
0
50
100
150
Aminothienopyridazine
VEH
Positive Control
Carbocyanine
Oleuropein
Hydroxytyrosol
Anthraquinone
Rhodanine
log Concentration (µM)
%
in
hi
bi
to
ry
AT
Pa
se
ac
tiv
ity
70 
 
 
Figure 3.5. Determination of LDH cytotoxicity of Hsp70 and Tau aggregation 
inhibitors in HEK293T cells. HEK293T cells (10,000 cells per well) were plated in a 96-
well plate and incubated overnight at 37°C. After 24 h, increasing concentrations of 
inhibitors were added to the culture media and incubated for 24 h at 37°C. LDH 
cytotoxicity was measured using the Pierce LDH Cytotoxicity Assay Kit. Values are 
relative to DMSO control. 
3.4 Materials and Methods 
3.4.1 Cell Culture 
HEK293T cells were maintained in DMEM plus 10% FBS (Life Technologies), 1% 
Penicilin Streptomycin (Invitrogen), and 1% Glutamax (complete media; Thermo 
Scientific). Transfections were performed following the Invitrogen Plasmid DNA 
Transfection protocol using Opti-MEM. All cells were treated as indicated and were 
harvested as previously described.9 Cells were washed twice in ice-cold PBS, then 
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scraped in cold mammalian protein extraction reagent (M-PER; Fisher Scientific) 
containing PMSF, protease and phosphatase inhibitors.  Samples were incubated on ice, 
vortexed, then centrifuged at 10,000 rpm for 5 min at 4°C to clear debris. Assays were 
run in triplicate and statistical significance was assessed by t-test. 
 
3.4.2 Aggregation Kinetics (Thioflavin T) Assay and Immunoblot 
Samples consisting of 10 µM purified human recombinant Tau P301L, 2 mM 
diothiothreitol, indicated drug concentration, 10 µM heparin, and 10 µM thioflavin T in 100 
mM sodium acetate buffer at pH 7.4 were prepared. 200 µL of indicated sample was 
added to a black, sealed, clear-bottom 96 well plate (Corning costar 3603). Plates were 
incubated at 37°C and fluorescence (440 emission, 490 excitation) was observed over a 
24 h time course, with periodic readings using a BioTek Synergy H1 microplate reader. 
Following ThT analyses, recombinant fibrils were analyzed by Native-PAGE (non-
denaturing conditions), followed by immunoblotting for tau. Specifically, samples 
incubated with 30µM of each compound were analyzed in this way. 
 
3.4.3 Hydrogen Peroxide Assay 
Hydrogen peroxide production was measured as previously described. 29 Briefly, 
recombinant human P301L tau (10 µM) was incubated with 30 µM rhodacyanine or 
equivalent vehicle (DMSO). Hydrogen peroxide production was measured using the 
PeroXQuant assay (Pierce 23280) according to manufacturer instructions. 
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3.4.4 Hsp70 ATPase Assay 
Recombinant human Hsp70 and DnaJA2 were used in a malachite green assay. A master 
mix of Hsp70:DnaJA2 at 1 µM prepared in assay buffer (0.017% Triton X-100, 100 mM 
Tris–HCl, 20 mM KCl, and 6 mM MgCl2, pH 7.4). An aliquot (14 μL) of this mixture was 
added into each well of a 96-well plate. To this solution, 1 μL of either compound (3, 10, 
30, 100, or 200 μM) or DMSO was added and the plate was incubated for 30 min at 37 
°C before adding 10 μL of 2.5 mM ATP to start the reaction. Thus, the final reaction 
volume was 25 μL and the conditions were 1 μM Hsp70, 1 μM DnaJA2, 4% DMSO, 0.01% 
Triton X-100, and 1 mM ATP. After 3 h incubation at 37 °C, 80 μL of malachite green 
reagent was added into each well. Immediately after this step, 10 μL 34% sodium citrate 
was used to stop the nonenzymatic hydrolysis of ATP. The samples were mixed 
thoroughly and incubated at 37 °C for 15 min before measuring OD620 on a BioTek 
Synergy H1 microplate reader as previously described.21 
 
3.4.5 Lactate Dehydrogenase (LDH) Assay 
LDH cytotoxicity was measured using the Pierce LDH Cytotoxicity Assay Kit. Values are 
presented as the percent of LDH release compared to DMSO (Vehicle) treated cells. 
 
3.4.6 Western Blotting 
After normalization of protein concentration by bicinchoninic acid (BCA) (ThermoFisher), 
samples were run on 10% SDS-PAGE gels (for non-denaturing gel electrophoresis 
samples were run without β- mercaptoethanol on a 4-15% gradient PAGE gel) and 
transferred to PVDF membranes (Immobilon, EMD Millipore).  Membranes were blocked 
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for 1 h in 7% nonfat dry milk in TBS-T before being probed with antibodies directed against 
total tau (H150; 1:1000; Santa Cruz Biotechnology), tau phosphorylated at S396/404 
(PHF1; 1:500; provided by P. Davies), ß-actin (1:1000; Sigma-Aldrich), or GAPDH 
(1:1000; Biodesign). Primary antibodies were detected by species appropriate secondary 
antibodies (Southern Biotech) and chemiluminescence was detected by ECL 
(ThermoFisher). Scion Image software was used to calculate densitometry of all western 
blots. All values are shown as percent vehicle following actin normalization ± standard 
error of the mean. 
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CHAPTER FOUR: 
 
FINAL PERSPECTIVES 
In our study we demonstrated that small molecules targeting tau degradation 
pathways are effective in enhancing tau turnover. We initially synthesized a natural 
product from bayberry root bark, myricanol, and found it could reduce tau levels in multiple 
models of tauopathy.1 We then discovered that one of its enantiomers, (+)-aR,11S-
myricanol (3), was responsible for its anti-tau activity.2 Moreover we revealed the 
mechanism of 3’s tau clearance to be the stimulation of macroautophagy.2 We lastly made 
derivatives of myricanol that did not depend on stereochemistry in order have anti-tau 
activity.2 This has given the field another small molecule besides rapamycin that can 
increase autophagic processing through macroautophagy to degrade client proteins such 
as tau. 
 In our next study we found that several known Hsp70 inhibitor scaffolds could 
lower cellular tau levels. We also discovered that many of the known tau aggregation 
inhibitor scaffolds unexpectedly did not lower tau levels. This then led us to investigate 
which activity, Hsp70 inhibition or tau aggregation inhibition, was more predictive of anti- 
tau activity. Interestingly, we found that both activities together were required to lower tau 
levels. We discovered this phenomenon from the active tau reducing Hsp70 inhibitors 
having in vitro anti-tau aggregation activity and the ineffective tau aggregation inhibitors 
not having anti-Hsp70 ATPase activity. There was even a positive correlation between 
the tau lowering and anti-tau aggregation activity of each tau lowering Hsp70 inhibitor. 
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This work serves to help improve the field’s screening strategies for tau expression 
reducing compounds. In addition this provides more scaffolds that can be further 
developed to treat tauopathies. 
 With this in mind one of the most successful clinical trial compounds to treat AD, 
FTD and other tauopathies has been the phenothiazine compound, methylene blue or 
LMTX®.3-5 As previously discussed in Chapters 1 and 3, MB can prevent tau aggregation, 
inhibit Hsp70, and improve autophagic processing.6-10 All of these activities we 
hypothesize can synergize together be an effective treatment.  However this strategy has 
not received more attention in the clinical setting due to lack of research showing the 
synergistic effects of combining tau aggregation inhibitors with inhibitors that can enhance 
proteasomal and/or autophagic degradation. Furthermore there have been a lack of 
candidate compounds known to possess both activities.  
While MB has been the most successful dual activity compound to date to treat 
tauopathies, we have shown that the rhodacyanine scaffold could be further developed 
and used clinically. We have demonstrated that the rhodacyanine scaffold is equally as 
potent in lowering tau levels as the phenothiazine scaffold. In addition the rhodacyanine 
scaffold not only prevents tau aggregation (Chapter 3) but also simultaneously promotes 
tau clearance through proteasomal degradation.11 Moreover our lab has characterized 
the structure-activity relationship (SAR) in these derivatives. We have identified several 
regions of this scaffold that could be modified to improve potency, blood brain barrier 
permeability or even bioavailability. These derivatives are shown in Table 4.1. 
Overall our findings suggest a new therapeutic approach should be considered for 
the treatment of tauopathies which is combination therapy. The use of dual acting 
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compounds such as MB and JG-98 or simultaneous treatments with a tau aggregation 
inhibitor and a tau degradation pathway stimulator will be most effective in preventing or 
stopping the devastating pathology in many tauopathies. 
 
Table 4.1. Structure-Activity Relationship of Rhodacyanine Derivatives. In HEK 
tau cells, ↓ indicates ≤ 30% reduction in tau at 30µM, ↓↓ indicates >30 but ≤ 60% reduction 
in tau 30µM, and ↓↓↓ indicates >60% but ≤ 90% reduction in tau at 30µM in cell culture. 
Toxicity was determined by cell proliferation MTS assay in HEK cells. + or – indicates 
>10% or <10% toxicity at 10µM in cell culture, respectively. No compounds showed 
>30% toxicity up to 30µM. If cell survival was < 90% at 10µM, drug was considered toxic. 
In slice cultures from mouse brain + or – indicates >30% or <30% reduction up to 100µM, 
respectively. 
  
 
1
3
4
5
6
2
7 8
9
10
11
12
13
R1 R2 R3 Hy Tau 
Activity 
(cells) 
Tau  
Activity 
(slices) 
Toxicity 
MTS 
assay 
(cells) 
H ethyl methyl 13-pyridyl ↓↓ + - 
H ethyl H 13-pyridyl ↓↓ + - 
2-Cl ethyl benzyl 13-thiazolyl ↓↓↓ + + 
2-CF3 ethyl benzyl 13-thiazolyl ↓↓↓ + + 
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Table 4.1 (Continued) 
2-CF3 ethyl methyl 13-pyridyl ↓↓ Not 
tested 
- 
2-CF3 methyl 
acetate 
methyl 13-pyridyl ↓ Not 
tested 
- 
2-CF3 methyl 
acetate 
benzyl 13-thiazolyl ↓ Not 
tested 
- 
2-CF3 ethyl methyl 13-thiazolyl ↓ Not 
tested 
- 
2-CF3 ethyl ethyl 13-thiazolyl ↓ Not 
tested 
- 
2-CF3 ethyl ethyl 13-pyridyl ↓↓ Not 
tested 
- 
2-CF3 ethyl H 13-pyridyl No 
Change 
Not 
tested 
- 
H methyl 
acetate 
H 13-pyridyl No 
Change 
Not 
tested 
- 
H methyl 
acetate 
H 13-thiazolyl No 
Change 
Not 
tested 
- 
2-CF3 methyl 
acetate 
H 13-pyridyl No 
Change 
Not 
tested 
- 
2-CF3 methyl 
acetate 
H 13-thiazolyl No 
Change 
Not 
tested 
- 
2-F methyl 
acetate 
H 13-pyridyl No 
Change 
Not 
tested 
- 
3-F methyl 
acetate 
H 13-pyridyl No 
Change 
Not 
tested 
- 
2-F methyl 
acetate 
H 15-pyridyl No 
Change 
Not 
tested 
- 
3-F methyl 
acetate 
H 15-pyridyl No 
Change 
Not 
tested 
- 
4-F methyl 
acetate 
H 13-pyridyl No 
Change 
Not 
tested 
- 
1-F methyl 
acetate 
H 13-pyridyl No 
Change 
Not 
tested 
- 
2-CF3 ethyl H 15-pyridyl No 
Change 
Not 
tested 
- 
2-F methyl ester 
propanoate 
H 13-pyridyl No 
Change 
Not 
tested 
- 
2-Cl ethyl H 13-thiazolyl No 
Change 
Not 
tested 
- 
2-CF3 ethyl H 13-thiazolyl No 
Change 
Not 
tested 
- 
3-
methyl 
ester 
ethyl methyl 13-pyridyl ↓ + - 
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H ethyl ethyl 
amine 
13-pyridyl ↓↓ + - 
H ethyl methyl 13-pyridyl, 
13-pyrazyl 
↓ + - 
2-F ethyl methyl 13-pyridyl ↓↓ + - 
3,4-
benzyl 
ethyl methyl 13-pyridyl ↓ + - 
2-NH2 ethyl methyl 13-pyridyl ↓↓ + - 
2-NO2 ethyl H 13-pyridyl No 
Change 
- - 
2-CF3 ethyl H 13-pyridyl No 
Change 
- - 
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Figure B.1. Synthetic racemic 1 reduces tau levels in a tauopathy cell model with 
low µM potency. Representative western blot of lysates from HEK293T cells stably 
overexpressing P301L tau (HEK P301L tau) treated with indicated concentrations of 
synthetic 1 for 24 h. 
Synthetic 1 (µM)
ptau
total tau
actin
0    3  10  30
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Figure B.2. (continued on next page) LC-MS spectra of 3 treated cell lysates. (A) 
Total ion current (TIC) chromatogram of untreated sample, (B) TIC of vehicle sample and 
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(C) TIC of the vehicle sample spiked with 3 at 300 µM. (D) Electrospray ionization (ESI) 
positive mode spectrum of the peak at the retention time (RT) 3.91 min representing the 
internal standard 3. (E) Overlaid extracted ion chromatogram (EIC) of 3 at m z-1 359.2 for 
cell lysates from HEK P301L cells treated with 3 at 30 µM for 1, 6 and 24 h incubation. 
 
Table B.1. Top activated and inactivated upstream regulators as determined by IPA 
software. The upstream regulators are chemicals or molecules predicted by IPA to 
explain the upregulated and downregulated genes observed in our dataset. Their 
activation state is determined by examining the known targets of each upstream regulator 
in our dataset and comparing those targets’ changes to expectations derived from IPA.  
The p-value of overlap is a measure of statistical significance with respect to the upstream 
regulator for our dataset and a reference set of molecules from IPA (which define the 
molecules that could possibly have been upstream regulators). The p-value is calculated 
with the right-tailed Fisher's Exact Test. 
Table B.1 Top activated and inactivated upstream 
regulators as determined by IPA software. 
Upstream Regulator Predicted 
Activation 
State 
p-value of 
overlap 
sirolimus/rapamycin Activated 4.19E-43 
PDGF (family) Activated 2.21E-06 
miR-1 (and other miRNAs 
w/seed GGAAUGU) 
Activated 1.75E-05 
nitrofurantoin Inhibited 6.40E-08 
methapyrilene Inhibited 4.38E-07 
mono-(2-
ethylhexyl)phthalate 
Inhibited 1.44E-05 
 
Table B.2. Top canonical pathways as determined by IPA software. The canonical 
pathways are well-characterized metabolic and cell signaling pathways established in 
IPA. The p-value is a measure of statistical significance with respect to each canonical 
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pathway for our dataset and a reference set of pathways from IPA (which define the 
molecules that could possibly have been pathways). The p-value is calculated with the 
right-tailed Fisher's Exact Test. 
Table B.2 Top canonical pathways as 
determined by IPA software. 
Top Canonical Pathways P-Value 
EIF2 Signaling 9.95E-
50 
Regulation of EIF4 and p70S6K 
Signaling 
3.13E-
24 
mTOR Signaling 1.23E-
16 
 
Table B.3. Upregulated or downregulated kinases as determined by IPA software. 
Negative values represent downregulated kinases and positive values represent up 
regulated kinases in in neuronal cells treated with 3 for 24 h relative to vehicle treated 
cells. The relevance to tau column shows the sites at which the specific kinases are 
known to phosphorylate tau. 
Table B.3 Upregulated or downregulated kinases as determined by IPA software. 
Fold 
Chang
e 
Symbol Entrez Gene Name Kinase Function 
based on UniProt 
Relevance to 
tau 
-1.064 TWF1 twinfilin actin-binding 
protein 1 
protein tyrosine 
kinase 9 
Unknown/NA 
-1.063 MAPK1 mitogen-activated protein 
kinase 1 
serine/threonine 
kinase 
pT153, 
T175/181, S422, 
S46, S212/214, 
S199/S202/T205
, S396/404 
-1.039 PRKAR1A protein kinase, 
regulatory, type I, alpha 
cAMP dependent 
protein kinase A  
T231, S262, 
S212/214, 
S199/S202/T205 
-1.017 CSNK2A1 casein kinase 2, alpha 1 
polypeptide 
serine/threonine 
kinase 
S199/S205/T205
, S396/404 
1.090 ALDH18A
1 
aldehyde dehydrogenase 
18 family, A1 
gluatmate 5-kinase 
activity 
Unknown/NA 
1.372 PKM pyruvate kinase, muscle ATP generating 
kinase 
Unknown/NA 
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Table B.4 Crystal data and structure refinement for Racemic (2 and 3). 
Identification code CSmyR 
Empirical formula C21H28O6 
Formula weight 376.43 
Temperature/K 99.98 
Crystal system monoclinic 
Space group P21/c 
a/Å 10.2863(7) 
b/Å 18.1078(13) 
c/Å 10.1523(7) 
α/° 90.00 
β/° 94.602(4) 
γ/° 90.00 
Volume/Å3 1884.9(2) 
Z 4 
ρcalcg/cm3 1.327 
µ mm-1 0.792 
F(000) 808.0 
Crystal size/mm3 0.05 × 0.03 × 0.02 
Radiation CuKα (λ = 1.54178) 
2Θ range for data collection/° 8.62 to 133.12 
Index ranges -11 ≤ h ≤ 12, -21 ≤ k ≤ 21, -12 ≤ l ≤ 12 
Reflections collected 21398 
Independent reflections 3327 [Rint = 0.0463, Rsigma = 0.0299] 
Data/restraints/parameters 3327/0/266 
Goodness-of-fit on F2 1.034 
Final R indexes [I>=2σ (I)] R1 = 0.0391, wR2 = 0.0877 
Final R indexes [all data] R1 = 0.0571, wR2 = 0.0948 
Largest diff. peak/hole / e Å-3 0.32/-0.21 
 
Table B.5 Crystal data and structure refinement for enantiopure 2. 
Identification code CS_pl_SmyR_thf_hex_0m 
Empirical formula C98.91H133.82O24.1 
Moiety formula 4(C21H26O5), 3.73(C4H8O), 0.37(O) 
Formula weight 1708.39 
Temperature/K 100(2) 
Crystal system hexagonal 
Space group P61 
a/Å 49.7851(12) 
b/Å 49.7851(12) 
c/Å 6.7498(2) 
α/° 90.00 
β/° 90.00 
γ/° 120.00 
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Table B.5 (Continued) 
Volume/Å3 14488.4(7) 
Z 6 
ρcalcg/cm3 1.175 
µ mm-1 0.675 
F(000) 5520.0 
Crystal size/mm3 0.5 × 0.03 × 0.02 
Radiation CuKα (λ = 1.54178) 
2Θ range for data collection/° 6.14 to 134.84 
Index ranges -59 ≤ h ≤ 58, -56 ≤ k ≤ 56, -7 ≤ l ≤ 7 
Reflections collected 75183 
Independent reflections 15952 [Rint = 0.1407, Rsigma = 0.1116] 
Data/restraints/parameters 15952/290/1242 
Goodness-of-fit on F2 1.038 
Final R indexes [I>=2σ (I)] R1 = 0.0862, wR2 = 0.2079 
Final R indexes [all data] R1 = 0.1303, wR2 = 0.2372 
Largest diff. peak/hole / e Å-3 0.45/-0.28 
Flack parameter 0.1(3) 
 
Table B.6 Results of Bijvoet-Pair Analysis and Bayesian Statistics for 
enantiopure 2.  
Space Group P61 
Wavelength    1.54178 
  
Bijvoet Pairs    6574 
Coverage ...       84 
DiffCalcMax.   448.66 
Outlier Crit   897.31 
Sigma Crit..     0.25 
Select Pairs        3 
Number Plus         1 
Number Minus        2 
Aver. Ratio     0.910 
RC .........    0.726 
  
Normal Prob. Plot 
Sample Size.     6395 
Corr. Coeff.    1.000 
Intercept ..    0.176 
Slope ......    0.906 
  
Bayesian Statistics 
Type ....... Gaussian 
Select Pairs     6395 
P2(true)....    1.000 
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Table B.6 (Continued) 
P3(true)....    0.937 
P3(rac-twin)    0.063 
P3(false) ..  0.2E-05 
G ..........   0.8473 
G (su) .....   0.3583 
Hooft y ....     0.08 
Hooft (su) .     0.18 
 
Table B.7 Crystal data and structure refinement for 13. 
Identification code MYR_R16_6_0m 
Empirical formula C21H26O5 
Moiety Formula C21H24O4, H2O 
Formula weight 358.42 
Temperature/K 99.99 
Crystal system tetragonal 
Space group I41/a 
a/Å 22.3255(10) 
b/Å 22.3255(10) 
c/Å 14.2555(7) 
α/° 90 
β/° 90 
γ/° 90 
Volume/Å3 7105.3(7) 
Z 16 
ρcalcg/cm3 1.340 
μ mm-1 0.771 
F(000) 3072.0 
Crystal size/mm3 0.18 × 0.15 × 0.14 
Radiation CuKα (λ = 1.54178) 
2Θ range for data collection/° 7.358 to 145.338 
Index ranges -27 ≤ h ≤ 27, -25 ≤ k ≤ 27, -17 ≤ l ≤ 17 
Reflections collected 21368 
Independent reflections 3529 [Rint = 0.0537, Rsigma = 0.0348] 
Data/restraints/parameters 3529/4/254 
Goodness-of-fit on F2 1.027 
Final R indexes [I>=2σ (I)] R1 = 0.0445, wR2 = 0.1166 
Final R indexes [all data] R1 = 0.0529, wR2 = 0.1231 
Largest diff. peak/hole / e Å-3 0.30/-0.23 
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B.10 Supplementary Methods 
B.10.1 Compound Synthesis 
4-(4-Benzyloxy-3-iodophenyl)butan-2-one (8). To a stirring suspension of 4-(4-
benzyloxy-phenyl)butan-2-one (7) (25.0 g, 98.4 mmol) in chloroform (150 mL) was added 
silver trifluoracetate (25.0 g, 113 mmol). A solution of iodine (28.7 g, 113 mmol) in 
chloroform (750 mL) was added dropwise over 2 h. After complete addition, the reaction 
was allowed to stir for 16 h after which the mixture was filtered and the filtrate was washed 
with saturated aqueous sodium thiosulfate (250 mL). The organic phase was dried over 
magnesium sulfate, filtered and concentrated at reduced pressure. The resulting crude 
product was purified through silica gel (300 g cartridge) eluting with a gradient of 0 to 40% 
ethyl acetate in hexanes. The pure fractions were combined and concentrated at reduced 
pressure to give 3 as a tan solid (24.0 g, 64%). 1H NMR (300 MHz, CDCl3) δ 7.62 (d, J= 
2.1 Hz, 1H), 7.51-7.45 (m, 2H), 7.42-7.28 (m, 3H), 7.08 (dd, J= 2.1, 8.2 Hz, 1H), 6.76 (d, 
J= 8.2 Hz, 1H), 5.11 (s, 2H), 2.82-2.68 (m, 4H), 2.13 (s, 3H). LRMS (ESI) [M+H]+ m z-1 
381.0. 
4-[4-Benzyloxy-3-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)phenyl]butan-
2-one (9). A stirring solution of 8 (10.0 g, 26.3 mmol), bis(pinacolato)diboron (8.0 g, 31.5 
mmol) and potassium acetate (7.75 g, 79.0 mmol) in anhydrous dimethyl sulfoxide (100 
mL) was degassed with nitrogen for 10 min. 1,1'-Bis(diphenylphosphino)ferrocene-
palladium(II)dichloride dichloromethane complex (2.15 g, 2.63 mmol) was added and the 
resulting suspension was heated at 80 °C for 2 h. The reaction mixture was cooled to 
ambient temperature and water (500 mL) was added. The mixture was extracted with 
ethyl acetate (3 x 350 mL). The organic extracts were combined, dried over magnesium 
sulfate, filtered and concentrated at reduced pressure. The resulting crude product was 
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purified through silica gel (300 g cartridge) eluting with a gradient of 0 to 20% ethyl acetate 
in hexanes. The pure fractions were combined and concentrated at reduced pressure to 
give 9 as a white solid (6.2 g, 62%). 1H NMR (300 MHz, CDCl3) δ = 7.60 (d, J= 7.3 Hz, 
1H), 7.59 - 7.57 (m, 1H), 7.50 (d, J= 2.3 Hz, 1H), 7.39 - 7.25 (m, 4H), 7.21 (dd, J= 2.5, 
8.4 Hz, 1H), 6.85 (d, J= 8.5 Hz, 1H), 5.09 (s, 2H), 2.87 - 2.81 (m, 2H), 2.76 - 2.70 (m, 2H), 
2.13 (s, 3H), 1.56 (s, 1H), 1.37 (s, 12H). LRMS (ESI) [M+H]+ m z-1 381.3. 
 3-(2-Benzyloxy-3,4-dimethoxyphenyl)propionaldehyde (5).  A stirring solution 
of 2-benzyloxy-1-bromo-3,4-dimethoxybenzene (4) (16 g, 49.5 mmol), allyl alcohol (3.70 
mL, 54.4 mmol), N-methyldicyclohexylamine (11.7 mL, 54.4 mmol), 2-(di-tert-butyl-
phosphanyl)-1-phenyl-1H-indole (1.00 g, 2.96 mmol) in DMF (192 mL) was degassed with 
nitrogen for 10 min. Bis(dibenzylideneacetone)palladium(0) (571 mg, 0.99 mmol) was 
added and the resulting suspension was heated at 100 °C for 3 h. The reaction mixture 
was cooled to ambient temperature and poured into dilute hydrochloric acid (0.5 N, 500 
mL). The mixture was extracted with ethyl acetate (3 x 250 mL). The organic extracts 
were combined, dried over magnesium sulfate, filtered and concentrated at reduced 
pressure. The resulting crude product was purified through silica gel (180 g cartridge) 
eluting with a gradient of 0 to 20% ethyl acetate in hexanes. The pure fractions were 
combined and concentrated at reduced pressure to give 5 as an amber oil (6.2 g, 53%). 1H 
NMR (300 MHz, CDCl3) δ = 9.69 (s, 1H), 7.46 - 7.31 (m, 5H), 6.86 - 6.78 (m, J= 8.5 Hz, 
1H), 6.66 - 6.59 (m, J= 8.5 Hz, 1H), 5.09 (s, 2H), 3.89 (s, 3H), 3.86 (s, 3H), 2.82 (t, J= 7.5 
Hz, 2H), 2.61 (t, J= 7.2 Hz, 2H). LRMS (ESI) [M+H]+ m z-1 301.2. 
3-(2-Benzyloxy-5-iodo-3,4-dimethoxyphenyl)propionaldehyde (6). To a 
stirring suspension of 3-(2-benzyloxy-3,4-dimethoxy-phenyl)propionaldehyde (5) (7.0 g, 
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23.3 mmol) in chloroform (50 mL) was added silver trifluoracetate (5.66 g, 25.6 mmol). A 
solution of iodine (6.5 g, 25.6 mmol) in chloroform (250 mL) was added dropwise over 2 
h. After complete addition, the reaction was allowed to stir for 16 h after which the mixture 
was filtered and the filtrate was washed with saturated aqueous sodium thiosulfate (150 
mL). The organic phase was dried over magnesium sulfate, filtered and concentrated at 
reduced pressure. The resulting crude product was purified through silica gel (180 g 
cartridge) eluting with a gradient of 0 to 30% ethyl acetate in hexanes. The pure fractions 
were combined and concentrated at reduced pressure to give 6 as a tan oil (7.3 g, 
74%). 1H NMR (300 MHz, CDCl3) δ = 9.70 (s, 1H), 7.44 - 7.33 (m, 5H), 7.29 (s, 1H), 5.07 
(s, 2H), 3.92 (s, 3H), 3.87 (s, 3H), 2.81 - 2.74 (m, 2H), 2.64 - 2.56 (m, 2H). LRMS (ESI) 
[M+H]+ m z-1 427.1. 
7-(2-Benzyloxy-5-iodo-3,4-dimethoxyphenyl)-1-[4-benzyloxy-3-(4,4,5,5-
tetramethyl-[1,3,2]dioxaborolan-2-yl)phenyl]hept-4-en-3-one (10). To a solution of 
diisopropylamine (0.81 mL, 5.76 mmol) in tetrahydrofuran (20 mL) under nitrogen at 0 °C 
was added n-butyllithium (2.5 M in hexanes, 2.2 mL, 5.5 mmol). After 15 min, the mixture 
was cooled to -78 °C and a solution of 9 (2.0 g, 5.24 mmol) in tetrahydrofuran (20 mL) 
was added dropwise over 15 min. After 45 min, a solution of 6 (2.14 g, 5.0 mmol) in 
tetrahydrofuran (20 mL) was added dropwise over 15 min. After 45 min, the reaction 
mixture was poured into saturated aqueous ammonium chloride (100 mL) and the mixture 
was allowed to warm to ambient temperature. The mixture was poured into water and 
was extracted with ethyl acetate (3 x 75 mL). The organic extracts were combined, dried 
over magnesium sulfate, filtered and concentrated at reduced pressure. The crude 
product was dissolved in toluene (60 mL), p-toluenesulfonic acid (100 mg) was added 
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and the mixture was heated at 90 °C for 3 h. The mixture was cooled to ambient 
temperature, diluted with ethyl acetate (75 mL) and extracted with saturated aqueous 
sodium hydrogen carbonate (50 mL). The organic extract was dried over magnesium 
sulfate, filtered and concentrated at reduced pressure. The resulting crude product was 
purified through silica gel (80 g cartridge) eluting with a gradient of 0 to 30% ethyl acetate 
in hexanes. The pure fractions were combined and concentrated at reduced pressure to 
give 10 as a colorless oil (1.55 g, 39% over 2 steps). 1H NMR (300 MHz, CDCl3) δ = 7.59 
(d, J= 7.3 Hz, 2H), 7.45 - 7.30 (m, 1H), 7.28 - 7.25 (m, 9H), 7.20 (dd, J= 2.3, 8.4 Hz, 1H), 
6.85 (d, J= 8.5 Hz, 1H), 6.74 (td, J= 6.8, 15.8 Hz, 1H), 6.01 (d, J= 15.8 Hz, 1H), 5.09 (s, 
2H), 5.04 (s, 2H), 3.90 (s, 3H), 3.88 (s, 3H), 2.85 - 2.73 (m, 4H), 2.68 - 2.53 (m, 2H), 2.35 
(q, J=  7.5 Hz, 2H), 1.36 (s, 12H). LRMS (ESI) [M+H]+ m z-1 789.3. 
3,15-Bis-benzyloxy-16,17-dimethoxy-tricyclo[12.3.1.12,6]nonadeca-
1(18),2,4,6(19),10,14,16-heptaen-9-one (11). A stirring solution of 10 (1.40 g, 1.78 
mmol), and potassium acetate (579 mg, 6.0 mmol) in anhydrous dimethyl sulfoxide (177 
mL) was degassed with nitrogen for 10 min. 1,1'-Bis(diphenylphosphino)ferrocene-
palladium(II)dichloride dichloromethane complex (150 mg, 0.18 mmol) was added and 
the resulting suspension was heated at 80 °C for 2 h. The reaction mixture was cooled to 
ambient temperature and water (700 mL) was added. The mixture was extracted with 
ethyl acetate (3 x 350 mL). The organic extracts were combined, dried over magnesium 
sulfate, filtered and concentrated at reduced pressure. The resulting crude product was 
purified through silica gel (80 g cartridge) eluting with a gradient of 0 to 20% ethyl acetate 
in hexanes. The pure fractions were combined and concentrated at reduced pressure to 
give 11 as a white solid (207 mg, 22%). 1H NMR (300 MHz, CDCl3) δ = 7.59 (d, J= 8.5 
97 
 
Hz, 1H) 7.52 - 7.47 (m, 2H), 7.45 - 7.26 (m, 8H), 7.05 (dd, J= 2.3, 8.5 Hz, 1H), 6.94 - 6.80 
(m, 2H), 6.54 (s, 1H), 6.39 (d, J= 15.5 Hz, 1H), 5.13 (br. s, 2H), 5.05 (br. s, 2H), 3.96 (s, 
3H), 3.79 (s, 3H), 3.22 -3.05 (m, 3H), 2.85 - 2.72 (m, 2H), 2.70 - 2.49 (m, 3H). LRMS (ESI) 
[M+H]+ m z-1 535.2. 
3,15-Dihydroxy-16,17-dimethoxy-tricyclo[12.3.1.12,6]nonadeca-
1(18),2,4,6(19),14,16-hexaen-9-one (myricanone, 12). A suspension of palladium on 
carbon (10%, 160 mg) in acetic acid (6 mL) was added a solution of 11 (182 mg) in acetic 
acid (10 mL). This suspension was shaken on a Parr apparatus under hydrogen (55 psi) 
for 20 h. The mixture was filtered through Celite, the bottle and filter cake was rinsed with 
methanol and the combined filtrates were concentrated at reduced pressure. The crude 
product was purified through silica gel (20 g cartridge) eluting with a gradient of 0 to 40% 
ethyl acetate in hexanes. The pure fractions were combined and concentrated at reduced 
pressure to give 12 as an oil which solidified on standing to a white solid (75 mg, 61%). 1H 
NMR (300 MHz, CDCl3) δ = 7.64 (s, 1H), 7.05 (dd, J= 2.2, 8.1 Hz, 1H), 6.88 (d, J= 8.2 
Hz, 1H), 6.74 (d, J= 2.1 Hz, 1H), 6.61 (s, 1H), 5.83 (s, 1H), 3.99 (s, 3H), 3.81 (s, 3H), 3.07 
- 2.97 (m, 2H), 2.83 - 2.70 (m, 6H), 1.98 - 1.82 (m, 4H). LRMS (ESI) [M+H]+ m z-1 357.2. 
16,17-Dimethoxy-tricyclo[12.3.1.12,6]nonadeca-1(18),2,4,6(19),14,16-
hexaene-3,9,15-triol (synthetic myricanol, 1). To a solution of myricanone (12) (75 mg, 
0.21 mmol) in tetrahydrofuran (4 mL) under nitrogen at -78 °C was added dropwise a 
solution of K-Selectride (1.0 M in THF, 0.84 mL, 0.84 mmol) and the reaction was allowed 
to warm to ambient temperature over 1 h. The reaction mixture was diluted with saturated 
aqueous ammonium chloride (15 mL) and extracted with ethyl acetate (3 x 25 mL). The 
combined organic extracts were dried over magnesium sulfate, filtered and concentrated 
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at reduced pressure. The crude product was purified through silica gel (12 g cartridge) 
eluting with a gradient of 0 to 50% ethyl acetate in hexanes. The pure fractions were 
combined and concentrated at reduced pressure to give 1 (60 mg, 80%). 1H NMR (300 
MHz, CDCl3) δ = 7.66 (s, 1H), 7.19 (d, J= 2.0 Hz, 1H), 7.10 (dd, J=  2.2, 8.2 Hz, 1H), 6.91 
(s, 1H), 6.90 (d, J= 8.2 Hz, 1H), 5.82 (br. s, 1H), 4.16 - 4.06 (m, 1H), 4.00 (s, 3H), 3.88 
(s, 3H), 2.94 – 2.85 (m, 2H), 2.81 (dt, J= 18, 2.4 Hz, 1H), 2.62 - 2.50 (m, 1H), 2.41 - 2.28 
(m, 1H), 2.00 - 1.88 (m, 3H), 1.76 - 1.66 (m, 2H), 1.62 - 1.52 (m, 3H). LRMS (ESI) 
[M+H]+ m z-1 359.1. 
(11S)‐4,5‐Dimethoxytetracyclo[9.7.1.02,7.015,19]nonadeca‐
1(18),2(7),3,5,15(19),16‐hexaene‐6,18‐diol (13). Myricanol (1) (50 mg) was treated in a 
solution of 10 mL of toluene with 79 mg of para toluene sulfonic acid. The solution was 
boiled for 24 h, cooled, diluted with hexane, washed successively with saturated solutions 
of NaHCO3 and NaCl, dried over MgSO4, and evaporated. The mixture was first purified 
by HPLC using normal phase with 3% ethyl acetate/hexane. The second fraction was 
separated using the same reverse phase condition and provided 21 mg of 13.  
White powder; [α]D21= 0.0 (c = 0.1, chloroform); UV (MeOH) λmax 286, 244 nm; IR (ATR, 
thin film) 3443, 2933, 2864, 1655, 1581, 1510, 1469, 1424, 1361, 1268, 1245, 1141, 1115, 
735 cm-1; 1H NMR (600 MHz, CDCl3) δ = 7.04 (H16, d, J= 8.3 Hz, 1H), 6.82 (H15, d, J= 
8.3 Hz, 1H), 6.35 (H2, s, 1H), 6.04 (5-OH, s, 1H), 4.99 (17-OH, brs, 1H), 3.98 (H21, s, 
3H), 3.83 (H20, s, 3H), 3.01 (H7b, dd, J= 13.2, 8.0 Hz, 1H), 2.89 (H13b, ddd, J= 16.8, 
8.0, 2.7 Hz, 1H), 2.80 (H13a, ddd, J= 17.3, 10.0, 8.0 Hz, 1H), 2.42 (H10, dt, J= 9.5, 3.1 
Hz, 1H), 1.99 (H12b, m, 1H), 1.97 (H8b, m, 1H), 1.86 (H7a, m, 1H), 1.72 (H12a, m, 1H), 
1.65 (H9, m, 2H), 1.60 (H11, m, 2H), 1.46 (H8a, m, 1H); 13C NMR (125 MHz, CDCl3) δ = 
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150.0 (C3), 149.9 (C17), 147.6 (C5), 142.8 (C18), 135.1 (C4), 130.1 (C16), 129.1 (C19), 
126.9 (C14), 125.1 (C1), 124.3 (C6), 112.5 (C15), 104.0 (C2), 61.0 (C21), 55.8 (C20), 
37.1 (C9), 34.3 (C10), 31.9 (C11), 27.5 (C8), 27.3 (C13), 25.2 (C7), 16.9 (C12). 70 eV 
HRMS (EI) [M+] m z-1 340.1653 (calcd for C21H24O4 340.1675). White powder re-
crystallized as colorless needles from acetonitrile/ water at room temperature. 
Crystallographic data for 13 registered as CCDC #1026945) can be obtained free of 
charge from The Cambridge Crystallographic Data Centre 
via www.ccdc.cam.ac.uk/data_request/cif. 
6,18-Dihydroxy-4,5-dimethoxytricyclo[13.3.1.02,7]nonadeca-
1(18),2(7),3,5,15(19),16-hexaen-12-one (isomyricanone, 15).  Myricanone (12, 41 mg, 
1.15 mmol) was added to boron trifluoride diethyl etherate (2.7 mL) under nitrogen and 
the reaction was heated at 45 °C for 48 h. The reaction mixture was cooled to ambient 
temperature and poured into water (25 mL). The aqueous layer was extracted with diethyl 
ether (3 x 25 mL) and the combined organic extracts were dried over magnesium sulfate, 
filtered and concentrated at reduced pressure. The crude product was purified through 
silica gel (4 g cartridge) eluting with a gradient of 0 to 25% ethyl acetate in hexanes. The 
pure fractions were combined and concentrated at reduced pressure to give 15 as a white 
solid (24 mg, 59%). 1H NMR (300 MHz, CDCl3) δ  = 7.13 (dd, J =8.4, 2.2 Hz, 1H), 7.11 
(d, J =8.4 Hz, 1H), 6.79 (d, J =2.3 Hz, 1H), 6.39 (s, 1H), 5.96 (s, 1H), 4.85 (s, 1H), 3.95 
(s, 3H), 3.84 (s, 3H), 3.02 (dt, J =3.4, 13.0 Hz, 1H), 2.80 (tt, J =13.5, 4.2 Hz, 1H), 2.57 (dt, 
J =3.4, 13.0 Hz, 1H), 2.41 (m, 2H), 2.11 (m, 2H), 1.95 (m, 2H), 1.75 (dt, J =2.7, 12.3 Hz, 
1H), 1.39 (m, 1H), 1.13 (m, 1H). 13C NMR (75 MHz, CDCl3) δ = 213.5, 151.4, 50.4, 148.8, 
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135.4, 132.1, 130.6, 130.4, 129.1, 126.8, 122.4, 116.1, 104.5, 61.1, 56.0, 44.6, 42.8, 33.4, 
26.9, 25.1, 21.0.  
4,5-Dimethoxy-tricyclo[13.3.1.02,7]nonadeca-1(18),2(7),3,5,15(19),16-
hexaene-6,12,18-triol (isomyricanol, 16). To a solution of isomyricanone (15, 20 mg, 
0.056 mmol) in methanol (0.60 mL) was added sodium borohydride (13 mg, 0.337 mmol) 
under nitrogen and the reaction was stirred at ambient temperature for 1 h. The reaction 
mixture was then quenched with water (15 mL) and the aqueous layer was extracted with 
ethyl acetate (3 x 20 mL). The combined organic extracts were dried over magnesium 
sulfate, filtered and concentrated at reduced pressure to give the product as a white solid 
(18 mg, 89%). 1H NMR (300 MHz, CDCl3) δ = 7.05 (dd, J= 8.4, 2.3 Hz, 1H), 6.94 (d, J= 
8.4 Hz, 1H), 6.89 (d, J= 2.1 Hz, 1H), 6.45 (s, 1H), 5.98 (s, 1H), 4.72 (s, 1H), 3.95 (m, 3H), 
3.84 (s, 3H), 3.69 (t, J= 8.8 Hz, 1H), 2.85 (tt, J= 13.4, 4.0 Hz, 1H), 2.66 (dt, J= 3.5, 13.1 
Hz, 1H), 2.48 (m, 1H), 1.95 (tt, J= 13.5, 4.0 Hz, 1H), 1.89-1.43 (m, 5H), 1.32 (m, 1H), 1.14 
(m, 1H), 0.92 (m, 1H), 0.66 (br t, J= 12.1 Hz, 1H). 13C NMR (75 MHz, CDCl3) δ = 151.1, 
150.4, 148.6, 135.4, 133.0, 131.5, 131.1, 129.3, 126.7, 122.5, 115.9, 104.6, 72.4, 61.1, 
56.0, 40.1, 35.2, 33.8, 26.7, 25.4, 24.0. HRMS (EI) [M+] m z-1 358.1823 (calcd for 
C21H26O5 348.1780) 
 
B.10.2 Chiral Separation 
Racemic myricanol (1) ([α]D20= +46.4) was separated by HPLC using a chiral 
column under solvent system 1 and the separation yielded 2 fractions eluting at 30.9 min 
and 47.4 min, corresponding to 2 [α]D22= +55.0 (c = 1.0, chloroform) and 3 [α]D22= -55.0 
(c = 1.0, chloroform). The scalemic 1 was dissolved in warm ethanol/ water then slowly 
cooled in the freezer at -20oC to provide high quality co-crystal needles wherein the co-
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former molecules are enantiomers 2 and 3. Racemic 13 was separated by HPLC using a 
chiral under solvent system 2 and the separation yielded 2 fractions eluting at 25.8 min 
and 29.8 min, corresponding to (-)-13 [α]D20= - 93.8 (c = 0.08, chloroform) and (+)-13 
[α]D20= +100 (c = 0.09, chloroform). And the pure enantiomer 2 was recrystallized from 
terahydrofuran/ hexane at 4oC. Crystallographic data for the racemic mixture 1 
(enantiomers 2/ 3 [1:1]) and the pure enantiomer 2 (registered as CCDC #1026943 and 
CCDC #1026944, respectively) can be obtained free of charge from The Cambridge 
Crystallographic Data Centre via www.ccdc.cam.ac.uk/data_request/cif. 
 
B.10.3 X-ray crystallography 
The X-ray diffraction data for the racemic (2 and 3), the pure enantiomer 2, and 
the racemic 13 were measured on a Bruker D8 Venture PHOTON 100 CMOS system 
equipped with a CuKα INCOATEC Imus micro-focus source (λ = 1.54178 Å). Indexing 
was performed using APEX21 (Difference Vectors method). Data integration and 
reduction were performed using SaintPlus 6.01.2 Absorption correction was performed by 
multi-scan method implemented in SADABS.3 Space groups were determined using 
XPREP implemented in APEX2.1 The structure was solved using SHELXS-97 (direct 
methods) and refined using SHELXL-97 4 (full-matrix least-squares on F2) contained in 
APEX2,1, 4 WinGX v1.70.01 4-7 and OLEX2.4, 8 All non-hydrogen atoms were refined 
anisotropically. Hydrogen atoms of –CH, -CH2 and -CH3 groups were placed in 
geometrically calculated positions and included in the refinement process using riding 
model with isotropic thermal parameters: Uiso(H) = 1.2(1.5)Ueq(-CH,-CH2(-CH3)). 
Racemic (2 and 3): Hydrogen atoms of water molecule and hydroxyl groups have 
been found from difference Fourier map and were freely refined. The remaining hydrogen 
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atoms were placed in geometrically calculated positions and included in the refinement 
process using riding model with isotropic thermal parameters: Uiso(H) = 1.2Ueq(-CH, -
CH2) and Uiso(H) = 1.5Ueq(-CH3). Crystal data and refinement conditions are shown in 
Table B.7. 
Enantiopure 2: Disordered THF molecules that are located in the structural voids 
have been refined using geometry and ADP restraints. Additionally the occupancy of 
disordered THF molecules has been refined as free variable for all but one disordered 
THF for which it was set to be 0.25. The hydrogen atoms were placed in geometrically 
calculated positions and included in the refinement process using riding model with 
isotropic thermal parameters: Uiso(H) = 1.2Ueq(-CH, -CH2) and Uiso(H) = 1.5Ueq(-CH3). 
There are four molecules of myricanol in asymmetric unit. The absolute configuration has 
been additionally verified by Bijvoet-Pair Analysis and Bayesian Statistic method 
implemented in program Platon,9, 10 in which the value of P2(true) gives the probability 
(scale 0 to 1) that the current absolute structure is the correct one, assuming that the 
compound is enantiopure. As can be seen from Table B.9 the P2 parameter equals 1 
suggesting the absolute configuration of the molecule is correct. Crystal data and 
refinement conditions are shown in Table B.8. 
Racemic 13: Hydrogen atoms of water molecules have been found from difference 
Fourier map and were refined using distance restraint and with Uiso(H) = 1.5Ueq(OH2O). 
One hydrogen atom of water molecule is disordered over two positions. Crystal data and 
refinement conditions are shown in Table B.9. 
 
B.10.4 SILAC sample preparation and analysis 
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Trypsin digestion: Samples were digested using a modified version of the filter 
aided sample preparation (FASP) method.11 Briefly, equal amounts of protein extract from 
each biological replicate were combined and diluted to ≤ 0.5% SDS in 8 M urea, 50 mM 
ammonium bicarbonate (AmBic). Samples were loaded onto 30 kDa molecular weight 
cutoff filters (Expedeon, San Diego, CA, USA) for buffer exchange to 8 M urea, 50 mM 
AmBic prior to alkylation of Cys residues by addition of iodoacetamide to 10 mM and 
incubation in the dark for 20 min at RT. Alkylation buffer was exchanged to 50 mM AmBic 
prior to addition of Promega (Madison, WI, USA) sequencing grade trypsin at a ratio of 
1:50 trypsin:protein. Digestions were performed by incubation at 37 °C overnight (16 – 20 
h). Trypsin activity was halted by addition of formic acid to 1% v/v.  
Desalting of digests: Desalting of peptide suspensions was performed on 
MacroSpin 300 Å C18 solid-phase extraction (SPE) spin columns (The Nest Group, Inc., 
Southborough, MA, USA) followed by “speed-vac” centrifugal vacuum concentration at 
50°C (Labconco, Kansas City, MO, USA). Samples were resuspended in 0.1% formic 
acid in water to a final concentration of 1 mg mL-1 for HPLC-MS/MS analysis.  
High-performance liquid chromatography-tandem mass spectrometric (HPLC-
MS/MS) analysis: Each duplex SILAC replicate was separated by nano-flow reversed-
phase HPLC on an Eksigent NanoLC 1D Plus system (Dublin, CA, USA). Five 
micrograms of each replicate was loaded onto a New Objective (Woburn, MA, USA) 150 
μm i.d. × 2.5 cm C18 capillary trap (5 µm particle, 300Å pore). Peptide ions were then 
transferred to and eluted from a CMP Scientific (Hoboken, NJ, USA) 75 μm i.d. × 10 cm 
analytical column with C18 on 5 μm silica beads with 300 Å pores by linear gradient of 2% 
- 40% acetonitrile, 0.1% formic acid over 180 min at a flow rate of 300 nL × min-1. Eluates 
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were delivered by electrospray ionization (ESI) at 2.5 kV and analyzed in positive ion 
mode on a hybrid linear ion trap-orbitrap mass spectrometer (LTQ XL Orbitrap, Thermo 
Scientific, San Jose, CA, USA) equipped with XCalibur (version 2.0.7) data acquisition 
software. Full MS scans were performed on m z-1 300 – 2000 at 60,000 resolution (FT 
analyzer) followed by data-dependent tandem MS (MS/MS) scans of the top-ten most 
intense precursor ions in the linear ion trap. Dynamic exclusion duration was set for 30 s 
with one repeat, a list size of 500, and a mass width of ± 10 ppm. Raw MS/MS spectral 
data were searched against a UniProt human FASTA database (148254 entries) including 
randomized and reversed sequences using MaxQuant version 1.3.0.5 (Max Planck 
Institute of Biochemistry, Martinsreid, Germany)12 Cys carbamidomethylation was 
selected as a fixed modification and Acetyl-protein N-terminus and Met-oxidation were 
selected as variable modification. Tryptic peptide pairs identified with a monoisotopic 
mass of 8 Da (Lys) or 10 Da (Arg) were selected for quantitation. Precursor FTMS 
tolerance was set for 6 ppm with ion trap tolerance set for 0.5 Da. Identification thresholds 
for both peptide and protein identifications were specified for ≤ 1 % false-discovery rate 
(FDR).  
 
B.10.5 Liquid Chromatography Mass Spectrometry (LC-MS) 
HEK293T P301L Cells were treated with 30 µM of 3 for 1, 6 and 24 h. Cells were 
lysed and harvested as described in cell culture section of the methods. One vehicle 
sample was spiked with a 10x concentration (300 µM) of 3 and used as positive control.  
Each cell lysate was first treated by a 5-minute centrifugation time at 14,000 g. The 
supernatant was then filtrated through a Hydrosart membrane (30,000 MWCO) during a 
15-minute centrifugation time at 14,000 g and 10 µL of the resulting filtrate was injected 
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on Agilent 1100 series LC-MS 6120 single quadrupole (LRESIMS) using a Phenomenex 
Kinetex C18 (2.6 µm, 3.0 x 50 mm) at 30oC under a linear gradient condition of 10% - 
100% ACNaq (+0.05% Formic acid) over 7 min, finishing at 100% ACNaq (+0.05% Formic 
acid) over 3 min at a flow rate of 1 mL × min-1. A full scan was performed on m z-1 100-
1000 amu for data acquisition using the Chemstation software and Mass Hunter software 
was used for data analysis. 
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APPENDIX C: 
 
Supporting Information for Chapter Three 
 
Figure C.1. Effects of Select Tau Modulating Compounds on P301L Tau stably 
transfected HEK293T Cells. Cells were treated with indicated concentrations of each 
compound or vehicle (-) for 24 h. Lysates were analyzed by western blot for tau and actin 
levels. A representative blot is shown for actin. 
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Figure C.2. Rhodacyanine does not significantly alter hydrogen peroxide 
production in the presence of tau, suggesting that cysteine oxidation is not 
occurring. Recombinant human P301L tau was incubated with compound for 1 h and 
levels of hydrogen peroxide were measured. Values are shown ± SEM. 
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Figure C.3. Hsp70 inhibitor compounds that also reduce tau aggregation are the 
most potent tau lowering agents. Correlation analyses comparing % tau lowering and 
% tau aggregation inhibition were performed for all Hsp70 inhibitors. A positive correlation 
was demonstrated between these two variables as determined by R square values after 
linear regression. 
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